Ocular disorder treatment methods and systems

Description

BACKGROUND OF THE INVENTION

Field of the Invention

The invention relates generally to medical devices and methods for reducing the intraocular pressure in an animal eye and, more particularly, to shunt type devices for permitting aqueous outflow from the eye's anterior chamber and associated methods thereof for the treatment of glaucoma.

Description of the Related Art

The human eye is a specialized sensory organ capable of light reception and able to receive visual images. The trabecular meshwork serves as a drainage channel and is located in anterior chamber angle formed between the iris and the cornea. The trabecular meshwork maintains a balanced pressure in the anterior chamber of the eye by draining aqueous humor from the anterior chamber.

About two percent of people in the United States have glaucoma. Glaucoma is a group of eye diseases encompassing a broad spectrum of clinical presentations, etiologies, and treatment modalities. Glaucoma causes pathological changes in the optic nerve, visible on the optic disk, and it causes corresponding visual field loss, resulting in blindness if untreated. Lowering intraocular pressure is the major treatment goal in all glaucomas.

In glaucomas associated with an elevation in eye pressure (intraocular hypertension), the source of resistance to outflow is mainly in the trabecular meshwork. The tissue of the trabecular meshwork allows the aqueous humor (“aqueous”) to enter Schlemm's canal, which then empties into aqueous collector channels in the posterior wall of Schlemm's canal and then into aqueous veins, which form the episcleral venous system. Aqueous humor is a transparent liquid that fills the region between the cornea, at the front of the eye, and the lens. The aqueous humor is continuously secreted by the ciliary body around the lens, so there is a constant flow of aqueous humor from the ciliary body to the eye's front chamber. The eye's pressure is determined by a balance between the production of aqueous and its exit through the trabecular meshwork (major route) or uveal scleral outflow (minor route). The trabecular meshwork is located between the outer rim of the iris and the back of the cornea, in the anterior chamber angle. The portion of the trabecular meshwork adjacent to Schlemm's canal (the juxtacanilicular meshwork) causes most of the resistance to aqueous outflow.

Glaucoma is grossly classified into two categories: closed-angle glaucoma, also known as angle closure glaucoma, and open-angle glaucoma. Closed-angle glaucoma is caused by closure of the anterior chamber angle by contact between the iris and the inner surface of the trabecular meshwork. Closure of this anatomical angle prevents normal drainage of aqueous humor from the anterior chamber of the eye.

Open-angle glaucoma is any glaucoma in which the angle of the anterior chamber remains open, but the exit of aqueous through the trabecular meshwork is diminished. The exact cause for diminished filtration is unknown for most cases of open-angle glaucoma. Primary open-angle glaucoma is the most common of the glaucomas, and it is often asymptomatic in the early to moderately advanced stage. Patients may suffer substantial, irreversible vision loss prior to diagnosis and treatment. However, there are secondary open-angle glaucomas which may include edema or swelling of the trabecular spaces (e.g., from corticosteroid use), abnormal pigment dispersion, or diseases such as hyperthyroidism that produce vascular congestion.

Current therapies for glaucoma are directed at decreasing intraocular pressure. Medical therapy includes topical ophthalmic drops or oral medications that reduce the production or increase the outflow of aqueous. However, these drug therapies for glaucoma are sometimes associated with significant side effects, such as headache, blurred vision, allergic reactions, death from cardiopulmonary complications, and potential interactions with other drugs. When drug therapy fails, surgical therapy is used. Surgical therapy for open-angle glaucoma consists of laser trabeculoplasty, trabeculectomy, and implantation of aqueous shunts after failure of trabeculectomy or if trabeculectomy is unlikely to succeed. Trabeculectomy is a major surgery that is widely used and is augmented with topically applied anticancer drugs, such as 5-flurouracil or mitomycin-C to decrease scarring and increase the likelihood of surgical success.

Approximately 100,000 trabeculectomies are performed on Medicare-age patients per year in the United States. This number would likely increase if the morbidity associated with trabeculectomy could be decreased. The current morbidity associated with trabeculectomy consists of failure (10-15%); infection (a lifelong risk of 2-5%); choroidal hemorrhage, a severe internal hemorrhage from low intraocular pressure, resulting in visual loss (1%); cataract formation; and hypotony maculopathy (potentially reversible visual loss from low intraocular pressure).

For these reasons, surgeons have tried for decades to develop a workable surgery for the trabecular meshwork.

The surgical techniques that have been tried and practiced are goniotomy/trabeculotomy and other mechanical disruptions of the trabecular meshwork, such as trabeculopuncture, goniophotoablation, laser trabecular ablation, and goniocurretage. These are all major operations and are briefly described below.

Goniotomy/Trabeculotomy: Goniotomy and trabeculotomy are simple and directed techniques of microsurgical dissection with mechanical disruption of the trabecular meshwork. These initially had early favorable responses in the treatment of open-angle glaucoma. However, long-term review of surgical results showed only limited success in adults. In retrospect, these procedures probably failed due to cellular repair and fibrosis mechanisms and a process of “filling in.” Filling in is a detrimental effect of collapsing and closing in of the created opening in the trabecular meshwork. Once the created openings close, the pressure builds back up and the surgery fails.

Trabeculopuncture: Q-switched Neodynium (Nd) YAG lasers also have been investigated as an optically invasive technique for creating full-thickness holes in trabecular meshwork. However, the relatively small hole created by this trabeculopuncture technique exhibits a filling-in effect and fails.

Goniophotoablation/Laser Trabecular Ablation: Goniophotoablation is disclosed by Berlin in U.S. Pat. No. 4,846,172 and involves the use of an excimer laser to treat glaucoma by ablating the trabecular meshwork. This was demonstrated not to succeed by clinical trial. Hill et al. used an Erbium:YAG laser to create full-thickness holes through trabecular meshwork (Hill et al., Lasers in Surgery and Medicine 11:341-346, 1991). This technique was investigated in a primate model and a limited human clinical trial at the University of California, Irvine. Although morbidity was zero in both trials, success rates did not warrant further human trials. Failure was again from filling in of surgically created defects in the trabecular meshwork by repair mechanisms. Neither of these is a viable surgical technique for the treatment of glaucoma.

Goniocurretage: This is an ab interno (from the inside), mechanically disruptive technique that uses an instrument similar to a cyclodialysis spatula with a microcurrette at the tip. Initial results were similar to trabeculotomy: it failed due to repair mechanisms and a process of filling in.

Although trabeculectomy is the most commonly performed filtering surgery, viscocanulostomy (VC) and non penetrating trabeculectomy (NPT) are two new variations of filtering surgery. These are ab externo (from the outside), major ocular procedures in which Schlemm's canal is surgically exposed by making a large and very deep scleral flap. In the VC procedure, Schlemm's canal is cannulated and viscoelastic substance injected (which dilates Schlemm's canal and the aqueous collector channels). In the NPT procedure, the inner wall of Schlemm's canal is stripped off after surgically exposing the canal.

Trabeculectomy, VC, and NPT involve the formation of an opening or hole under the conjunctiva and scleral flap into the anterior chamber, such that aqueous humor is drained onto the surface of the eye or into the tissues located within the lateral wall of the eye. These surgical operations are major procedures with significant ocular morbidity. When trabeculectomy, VC, and NPT are thought to have a low chance for success, a number of implantable drainage devices have been used to ensure that the desired filtration and outflow of aqueous humor through the surgical opening will continue. The risk of placing a glaucoma drainage device also includes hemorrhage, infection, and diplopia (double vision).

Examples of implantable shunts and surgical methods for maintaining an opening for the release of aqueous humor from the anterior chamber of the eye to the sclera or space beneath the conjunctiva have been disclosed in, for example, U.S. Pat. No. 6,059,772 to Hsia et al., and U.S. Pat. No. 6,050,970 to Baerveldt.

All of the above surgeries and variations thereof have numerous disadvantages and moderate success rates. They involve substantial trauma to the eye and require great surgical skill in creating a hole through the full thickness of the sclera into the subconjunctival space. The procedures are generally performed in an operating room and have a prolonged recovery time for vision.

The complications of existing filtration surgery have prompted ophthalmic surgeons to find other approaches to lowering intraocular pressure.

The trabecular meshwork and juxtacanilicular tissue together provide the majority of resistance to the outflow of aqueous and, as such, are logical targets for surgical removal in the treatment of open-angle glaucoma. In addition, minimal amounts of tissue are altered and existing physiologic outflow pathways are utilized.

As reported in Arch. Ophthalm. (2000) 118:412, glaucoma remains a leading cause of blindness, and filtration surgery remains an effective, important option in controlling the disease. However, modifying existing filtering surgery techniques in any profound way to increase their effectiveness appears to have reached a dead end. The article further states that the time has come to search for new surgical approaches that may provide better and safer care for patients with glaucoma.

Therefore, there is a great clinical need for a method of treating glaucoma that is faster, safer, and less expensive than currently available modalities.

SUMMARY OF THE INVENTION

The trabecular meshwork and juxtacanilicular tissue together provide the majority of resistance to the outflow of aqueous and, as such, are logical targets for surgical approach in the treatment of glaucoma. Various embodiments of glaucoma shunts are disclosed herein for aqueous to exit through the trabecular meshwork (major route) or uveal scleral outflow (minor route) or other route effective to reduce intraocular pressure (IOP).

Glaucoma surgical morbidity would greatly decrease if one were to bypass the focal resistance to outflow of aqueous only at the point of resistance, and to utilize remaining, healthy aqueous outflow mechanisms. This is in part because episcleral aqueous humor exerts a backpressure that prevents intraocular pressure from going too low, and one could thereby avoid hypotony. Thus, such a surgery would virtually eliminate the risk of hypotony-related maculopathy and choroidal hemorrhage. Furthermore, visual recovery would be very rapid, and the risk of infection would be very small, reflecting a reduction in incidence from 2-5% to about 0.05%.

U.S. application Ser. No. 09/549,350, filed Apr. 14, 2000, entitled APPARATUS AND METHOD FOR TREATING GLAUCOMA, now U.S. Pat. No. 6,638,239, and U.S. application Ser. No. 09/704,276, filed Nov. 1, 2000, entitled GLAUCOMA TREATMENT DEVICE, now U.S. Pat. No. 6,736,791, disclose devices and methods of placing a trabecular shunt ab interno, i.e., from inside the anterior chamber through the trabecular meshwork, into Schlemm's canal. The entire contents of each of these patent applications are hereby incorporated by reference herein. The invention encompasses both ab interno and ab externo glaucoma shunts or stents and methods thereof.

Techniques performed in accordance with aspects herein may be referred to generally as “trabecular bypass surgery.” Advantages of this type of surgery include lowering intraocular pressure in a manner which is simple, effective, disease site-specific, and can potentially be performed on an outpatient basis.

Generally, trabecular bypass surgery (TBS) creates an opening, a slit, or a hole through trabecular meshwork with minor microsurgery. TBS has the advantage of a much lower risk of choroidal hemorrhage and infection than prior techniques, and it uses existing physiologic outflow mechanisms. In some aspects, this surgery can potentially be performed under topical or local anesthesia on an outpatient basis with rapid visual recovery. To prevent “filling in” of the hole, a biocompatible elongated device is placed within the hole and serves as a stent. U.S. patent application Ser. No. 09/549,350, filed Apr. 14, 2000, now U.S. Pat. No. 6,638,239, the entire contents of which are hereby incorporated by reference herein, discloses trabecular bypass surgery.

As described in U.S. patent application Ser. No. 09/549,350, filed Apr. 14, 2000, now U.S. Pat. No. 6,638,239, and U.S. application Ser. No. 09/704,276, filed Nov. 1, 2000, now U.S. Pat. No. 6,736,791, the entire contents each one of which are hereby incorporated by reference herein, a trabecular shunt or stent for transporting aqueous humor is provided. The trabecular stent includes a hollow, elongate tubular element, having an inlet section and an outlet section. The outlet section may optionally include two segments or elements, adapted to be positioned and stabilized inside Schlemm's canal. In one embodiment, the device appears as a “T” shaped device.

In one aspect of the invention, a delivery apparatus (or “applicator”) is used for placing a trabecular stent through a trabecular meshwork of an eye. Certain embodiments of such a delivery apparatus are disclosed in U.S. application Ser. No. 10/101,548, filed Mar. 18, 2002, entitled APPLICATOR AND METHODS FOR PLACING A TRABECULAR SHUNT FOR GLAUCOMA TREATMENT, published as U.S. Publication No. 2002/0133168 and now abandoned, and U.S. Provisional Application No. 60/276,609, filed Mar. 16, 2001, entitled APPLICATOR AND METHODS FOR PLACING A TRABECULAR SHUNT FOR GLAUCOMA TREATMENT, the entire contents of each one of which are hereby incorporated by reference herein.

The stent has an inlet section and an outlet section. The delivery apparatus includes a handpiece, an elongate tip, a holder and an actuator. The handpiece has a distal end and a proximal end. The elongate tip is connected to the distal end of the handpiece. The elongate tip has a distal portion and is configured to be placed through a corneal incision and into an anterior chamber of the eye. The holder is attached to the distal portion of the elongate tip. The holder is configured to hold and release the inlet section of the trabecular stent. The actuator is on the handpiece and actuates the holder to release the inlet section of the trabecular stent from the holder. When the trabecular stent is deployed from the delivery apparatus into the eye, the outlet section is positioned in substantially opposite directions inside Schlemm's canal. In one embodiment, a deployment mechanism within the delivery apparatus includes a push-pull type plunger.

Some aspects of the invention relate to devices for reducing intraocular pressure by providing outflow of aqueous from an anterior chamber of an eye. The device generally comprises an elongated tubular member and cutting means. The tubular member is adapted for extending through a trabecular meshwork of the eye. The tubular member generally comprises a lumen having an inlet port and an outlet port for providing a flow pathway. The cutting means is mechanically connected to the tubular member for creating an incision in the trabecular meshwork for receiving at least a portion of the tubular member.

In one aspect, a self-trephining glaucoma stent is provided for reducing and/or balancing intraocular pressure in an eye. The stent generally comprises a snorkel and a curved blade. The snorkel generally comprises an upper seat for stabilizing said stent within the eye, a shank and a lumen. The shank is mechanically connected to the seat and is adapted for extending through a trabecular meshwork of the eye. The lumen extends through the snorkel and has at least one inlet flow port and at least one outlet flow port. The blade is mechanically connected to the snorkel. The blade generally comprises a cutting tip proximate a distal-most point of the blade for making an incision in the trabecular meshwork for receiving the shank.

Some aspects of the invention relate to methods of implanting a trabecular stent device in an eye. In one aspect, the device has a snorkel mechanically connected to a blade. The blade is advanced blade through a trabecular meshwork of the eye to cut the trabecular meshwork and form an incision therein. At least a portion of the snorkel is inserted in the incision to implant the device in the eye.

Some aspects provide a self-trephining glaucoma stent and methods thereof which advantageously allow for a “one-step” procedure in which the incision and placement of the stent are accomplished by a single device and operation. This desirably allows for a faster, safer, and less expensive surgical procedure. In any of the embodiments, fiducial markings, indicia, or the like and/or positioning of the stent device in a preloaded applicator may be used for proper orientation and alignment of the device during implantation.

Among the advantages of trabecular bypass surgery is its simplicity. The microsurgery may potentially be performed on an outpatient basis with rapid visual recovery and greatly decreased morbidity. There is a lower risk of infection and choroidal hemorrhage, and there is a faster recovery, than with previous techniques.

For purposes of summarizing the invention, certain aspects, advantages and novel features of the invention have been described herein above. Of course, it is to be understood that not necessarily all such advantages may be achieved in accordance with any particular embodiment of the invention. Thus, the invention may be embodied or carried out in a manner that achieves or optimizes one advantage or group of advantages as taught or suggested herein without necessarily achieving other advantages as may be taught or suggested herein.

All of these embodiments are intended to be within the scope of the invention herein disclosed. These and other embodiments of the invention will become readily apparent to those skilled in the art from the following detailed description of the preferred embodiments having reference to the attached figures, the invention not being limited to any particular preferred embodiment(s) disclosed.

BRIEF DESCRIPTION OF THE DRAWINGS

Having thus summarized the general nature of the invention and some of its features and advantages, certain preferred embodiments and modifications thereof will become apparent to those skilled in the art from the detailed description herein having reference to the figures that follow, of which:

FIG. 1 is a coronal cross-sectional view of an eye;

FIG. 2 is an enlarged cross-sectional view of an anterior chamber angle of the eye of FIG. 1;

FIG. 3 is a simplified partial view of an eye illustrating the implantation of a glaucoma stent having features and advantages in accordance with one embodiment of the invention;

FIG. 4 is a side elevation view of the stent of FIG. 3;

FIG. 5 is a top plan view of the stent of FIG. 3;

FIG. 6 is a bottom plan view of the stent of FIG. 3;

FIG. 7 is a front end view of the stent of FIG. 3 (along line 7-7 of FIG. 4);

FIG. 8 is a rear end view of the stent of FIG. 3 (along line 8-8 of FIG. 4);

FIG. 9 is an enlarged top plan view of a cutting tip of the stent of FIG. 3;

FIG. 10 is a top plan view of one exemplary embodiment of a snorkel top seating surface;

FIG. 11 is a top plan view of another exemplary embodiment of a snorkel top seating surface;

FIG. 12 is a top plan view of yet another exemplary embodiment of a snorkel top seating surface;

FIG. 13 is a top plan view of still another exemplary embodiment of a snorkel top seating surface;

FIG. 14 is a simplified partial view of an eye illustrating the implantation of a glaucoma stent having features and advantages in accordance with another embodiment of the invention;

FIG. 15 is a simplified partial view of an eye illustrating the implantation of a glaucoma stent having features and advantages in accordance with a further embodiment of the invention;

FIG. 16 is a side elevation view of a glaucoma stent having features and advantages in accordance with one embodiment of the invention;

FIG. 17 is a top plan view of the stent of FIG. 16;

FIG. 18 is a bottom plan view of the stent of FIG. 16;

FIG. 19 is a front end view along line 19-19 of FIG. 16;

FIG. 20 is a rear end view along line 20-20 of FIG. 16;

FIG. 21 is a side elevation view of a glaucoma stent having features and advantages in accordance with one embodiment of the invention;

FIG. 22 is a top plan view of the stent of FIG. 21;

FIG. 23 is a bottom plan view of the stent of FIG. 21;

FIG. 24 is a front end view along line 24-24 of FIG. 21;

FIG. 25 is a rear end view along line 25-25 of FIG. 21;

FIG. 26 is a front elevation view of a glaucoma stent having features and advantages in accordance with one embodiment of the invention;

FIG. 27 is a side elevation view along line 27-27 of FIG. 26;

FIG. 28 is a rear end view along line 28-28 of FIG. 26;

FIG. 29 is a simplified partial view of an eye illustrating the temporal implantation of a glaucoma stent using a delivery apparatus having features and advantages in accordance with one embodiment of the invention;

FIG. 30 is an oblique elevational view of an articulating arm stent delivery/retrieval apparatus having features and advantages in accordance with one embodiment of the invention;

FIG. 31 is a simplified partial view of an eye illustrating the implantation of a glaucoma stent using a delivery apparatus crossing through the eye anterior chamber;

FIG. 32 is a simplified partial view of an eye illustrating the implantation of a glaucoma stent having features and advantages in accordance with one embodiment of the invention;

FIG. 33 is a detailed enlarged view of the barbed pin of FIG. 32;

FIG. 34 is a simplified partial view of an eye illustrating the implantation of a glaucoma stent having features and advantages in accordance with one embodiment of the invention;

FIG. 35 is a simplified partial view of an eye illustrating the implantation of a glaucoma stent having features and advantages in accordance with one embodiment of the invention;

FIG. 36 is a simplified partial view of an eye illustrating the implantation of a glaucoma stent having features and advantages in accordance with one embodiment of the invention;

FIG. 37 is a simplified partial view of an eye illustrating the implantation of a glaucoma stent having features and advantages in accordance with one embodiment of the invention;

FIG. 38 is a simplified partial view of an eye illustrating the implantation of a glaucoma stent having features and advantages in accordance with one embodiment of the invention;

FIG. 39 is a simplified partial view of an eye illustrating the implantation of a glaucoma stent having features and advantages in accordance with one embodiment of the invention;

FIG. 40 is a simplified partial view of an eye illustrating the implantation of a glaucoma stent having features and advantages in accordance with one embodiment of the invention;

FIG. 41 is a simplified partial view of an eye illustrating the implantation of a glaucoma stent having features and advantages in accordance with one embodiment of the invention;

FIG. 42 is a simplified partial view of an eye illustrating the implantation of a glaucoma stent having features and advantages in accordance with one embodiment of the invention;

FIG. 43 is a simplified partial view of an eye illustrating the implantation of a valved tube stent device having features and advantages in accordance with one embodiment of the invention;

FIG. 44 is a simplified partial view of an eye illustrating the implantation of an osmotic membrane device having features and advantages in accordance with one embodiment of the invention;

FIG. 45 is a simplified partial view of an eye illustrating the implantation of a glaucoma stent using ab externo procedure having features and advantages in accordance with one embodiment of the invention;

FIG. 46 is a simplified partial view of an eye illustrating the implantation of a glaucoma stent having features and advantages in accordance with a modified embodiment of the invention; and

FIG. 47 is a simplified partial view of an eye illustrating the implantation of a drug release implant having features and advantages in accordance with one embodiment of the invention.

FIG. 48 is an oblique elevational view of a trabecular shunt applicator with a retractable blade mechanism.

FIGS. 49A and 49B are schematic cross sections of a trabecular punch device.

FIGS. 50A and 50B are elevational views of a control arm and trabeculotomy device for the trabecular shunt applicator.

FIGS. 51A through 51C are schematic oblique elevational views of various trabecular meshwork punching and drilling devices.

FIG. 52 is a perspective view illustrating a seton implant positioned within the tissue of an eye.

FIG. 53 is an alternate exemplary method for placing a seton implant at the implant site.

FIG. 54 illustrates a cut/install tool for forming a trabecular meshwork incision and for installing an intraocular pressure relief device.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The preferred embodiments of the invention described herein relate particularly to surgical and therapeutic treatment of glaucoma through reduction of intraocular pressure. While the description sets forth various embodiment specific details, it will be appreciated that the description is illustrative only and should not be construed in any way as limiting the invention. Furthermore, various applications of the invention, and modifications thereto, which may occur to those who are skilled in the art, are also encompassed by the general concepts described herein.

FIG. 1 is a cross-sectional view of an eye 10, while FIG. 2 is a close-up view showing the relative anatomical locations of a trabecular meshwork 21, an anterior chamber 20, and a Schlemm's canal 22. A sclera 11 is a thick collagenous tissue which covers the entire eye 10 except a portion which is covered by a cornea 12.

Referring to FIGS. 1 and 2, the cornea 12 is a thin transparent tissue that focuses and transmits light into the eye and through a pupil 14, which is a circular hole in the center of an iris 13 (colored portion of the eye). The cornea 12 merges into the sclera 11 at a juncture referred to as a limbus 15. A ciliary body 16 extends along the interior of the sclera 11 and is coextensive with a choroid 17. The choroid 17 is a vascular layer of the eye 10, located between the sclera 11 and a retina 18. An optic nerve 19 transmits visual information to the brain and is the anatomic structure that is progressively destroyed by glaucoma.

Still referring to FIGS. 1 and 2, the anterior chamber 20 of the eye 10, which is bound anteriorly by the cornea 12 and posteriorly by the iris 13 and a lens 26, is filled with aqueous humor (hereinafter referred to as “aqueous”). Aqueous is produced primarily by the ciliary body 16, then moves anteriorly through the pupil 14 and reaches an anterior chamber angle 25, formed between the iris 13 and the cornea 12.

As best illustrated by the drawing of FIG. 2, in a normal eye, aqueous is removed from the anterior chamber 20 through the trabecular meshwork 21. Aqueous passes through the trabecular meshwork 21 into Schlemm's canal 22 and thereafter through a plurality of aqueous veins 23, which merge with blood-carrying veins, and into systemic venous circulation. Intraocular pressure is maintained by an intricate balance between secretion and outflow of aqueous in the manner described above. Glaucoma is, in most cases, characterized by an excessive buildup of aqueous in the anterior chamber 20 which leads to an increase in intraocular pressure. Fluids are relatively incompressible, and thus intraocular pressure is distributed relatively uniformly throughout the eye 10.

As shown in FIG. 2, the trabecular meshwork 21 is adjacent a small portion of the sclera 11. Exterior to the sclera 11 is a conjunctiva 24. Traditional procedures that create a hole or opening for implanting a device through the tissues of the conjunctiva 24 and sclera 11 involve extensive surgery, as compared to surgery for implanting a device, as described herein, which ultimately resides entirely within the confines of the sclera 11 and cornea 12.

Self-Trephining Glaucoma Stent

FIG. 3 generally illustrates the use of one embodiment of a trabecular stenting device 30 for establishing an outflow pathway, passing through the trabecular meshwork 21, which is discussed in greater detail below. FIGS. 4-9 are different views of the stent 30. Advantageously, and as discussed in further detail later herein, the self-trephining-stent allows a one-step procedure to make an incision in the trabecular mesh 21 and place the stent or implant 30 at the desired or predetermined position within the eye 10. Desirably, this facilitates the overall surgical procedure.

In the illustrated embodiment of FIGS. 3-9, the shunt or stent 30 generally comprises a snorkel 32 and a main body portion or blade 34. The snorkel 32 and blade 34 are mechanically connected to or in mechanical communication with one another. The stent 30 and/or the body portion 34 have a generally longitudinal axis 36.

In the illustrated embodiment of FIGS. 3-9, the stent 30 comprises an integral unit. In modified embodiments, the stent 30 may comprise an assembly of individual pieces or components. For example, the stent 30 may comprise an assembly of the snorkel 32 and blade 34.

In the illustrated embodiment of FIGS. 3-9, the snorkel 32 is in the form of a generally elongate tubular member and generally comprises an upper seat, head or cap portion 38, a shank portion 40 and a lumen or passage 42 extending therethrough. The seat 38 is mechanically connected to or in mechanical communication with the shank 40 which is also mechanically connected to or in mechanical communication with the blade 34. The snorkel 32 and/or the lumen 42 have a generally longitudinal axis 43.

In the illustrated embodiment of FIGS. 3-9, the seat 38 is generally circular in shape and has an upper surface 44 and a lower surface 46 which, as shown in FIG. 3, abuts or rests against the trabecular meshwork 21 to stabilize the glaucoma stent 30 within the eye 10. In modified embodiments, the seat 38 may efficaciously be shaped in other suitable manners, as required or desired, giving due consideration to the goals of stabilizing the glaucoma stent 30 within the eye 10 and/or of achieving one or more of the benefits and advantages as taught or suggested herein. For example, the seat 38 may be shaped in other polygonal or non-polygonal shapes and/or comprise one or more ridges which extend radially outwards, among other suitable retention devices.

In the illustrated embodiment of FIGS. 3-9, and as best seen in the top view of FIG. 5, the seat top surface 44 comprises fiducial marks or indicia 48. These marks or indicia 48 facilitate and ensure proper orientation and alignment of the stent 30 when implanted in the eye 10. The marks or indicia 48 may comprise visual differentiation means such as color contrast or be in the form of ribs, grooves, or the like. Alternatively, or in addition, the marks 48 may provide tactile sensory feedback to the surgeon. Also, the seat 38 and/or the seat top surface 44 may be configured in predetermined shapes aligned with the blade 34 and/or longitudinal axis 36 to provide for proper orientation of the stent device 30 within the eye 10. For example, the seat top surface 44 may be oval or ellipsoidal (FIG. 10), rectangular (FIG. 11), hexagonal (FIG. 12), among other suitable shapes (e.g. FIG. 13).

In the illustrated embodiment of FIGS. 3-9, and as indicated above, the seat bottom surface 46 abuts or rests against the trabecular meshwork 21 to stabilize and retain the glaucoma stent 30 within the eye 10. For stabilization purposes, the seat bottom surface 46 may comprise a studded surface, a ribbed surface, a surface with pillars, a textured surface, or the like.

In the illustrated embodiment of FIGS. 3-9, the snorkel shank 40 is generally cylindrical in shape. With the stent 30 implanted, as shown in FIG. 3, the shank 40 is generally positioned in an incision or cavity 50 formed in the trabecular meshwork 21 by the self-trephining stent 30. Advantageously, and as discussed further below, this single step of forming the cavity 50 by the stent 30 itself and placing the stent 30 in the desired position facilitates and expedites the overall surgical procedure. In modified embodiments, the snorkel shank 40 may efficaciously be shaped in other suitable manners, as required or desired. For example, the shank 40 may be in the shape of other polygonal or non-polygonal shapes, such as, oval, elliposoidal, and the like.

In the illustrated embodiment of FIGS. 3-9, and as best seen in FIG. 3, the shank 40 has an outer surface 52 in contact with the trabecular meshwork 21 surrounding the cavity 50. For stabilization purposes, the shank outer surface 52 may comprise a studded surface, a ribbed surface, a surface with pillars, a textured surface, or the like.

In the illustrated embodiment of FIGS. 3-9, the snorkel lumen 42 has an inlet port, opening or orifice 54 at the seat top surface 44 and an outlet port, opening or orifice 56 at the junction of the shank 40 and blade 34. The lumen 42 is generally cylindrical in shape, that is, it has a generally circular cross-section, and its ports 54, 56 are generally circular in shape. In modified embodiments, the lumen 42 and ports 54, 56 may be efficaciously shaped in other manners, as required or desired, giving due consideration to the goals of providing sufficient aqueous outflow and/or of achieving one or more of the benefits and advantages as taught or suggested herein. For example, the lumen 42 and/or one or both ports 54, 56 may be shaped in the form of ovals, ellipsoids, and the like, or the lumen 42 may have a tapered or stepped configuration.

Referring in particular to FIG. 3, aqueous from the anterior chamber 20 flows into the lumen 42 through the inlet port 54 (as generally indicated by arrow 58) and out of the outlet port 56 and into Schlemm's canal 22 (as generally indicated by arrows 60) to lower and/or balance the intraocular pressure (IOP). In another embodiment, as discussed in further detail below, one or more of the outlet ports may be configured to face in the general direction of the stent longitudinal axis 36. In modified embodiments, the snorkel 32 may comprise more than one lumen, as needed or desired, to facilitate multiple aqueous outflow transportation into Schlemm's canal 22.

In the illustrated embodiment of FIGS. 3-9, the blade longitudinal axis 36 and the snorkel longitudinal axis 43 are generally perpendicular to one another. Stated differently, the projections of the axes 36, 43 on a common plane which is not perpendicular to either of the axes 36, 43 intersect at 90°. The blade longitudinal axis 36 and the snorkel longitudinal axis 43 may intersect one another or may be offset from one another.

In the illustrated embodiment of FIGS. 3-9, the main body portion or blade 34 is a generally curved elongated sheet- or plate-like structure with an upper curved surface 62 and a lower curved surface 64 which defines a trough or open face channel 66. The perimeter of the blade 34 is generally defined by a curved proximal edge 68 proximate to the snorkel 32, a curved distal edge 70 spaced from the proximal edge 68 by a pair of generally straight lateral edges 72, 74 with the first lateral edge 72 extending beyond the second lateral edge 74 and intersecting with the distal edge 70 at a distal-most point 76 of the blade 34 proximate a blade cutting tip 78.

In the illustrated embodiment of FIGS. 3-9, and as shown in the enlarged view of FIG. 9, the cutting tip 78 comprises a first cutting edge 80 on the distal edge 70 and a second cutting edge 82 on the lateral edge 72. The cutting edges 80, 82 preferably extend from the distal-most point 76 of the blade 34 and comprise at least a respective portion of the distal edge 70 and lateral edge 72. The respective cutting edges 80, 82 are formed at the sharp edges of respective beveled or tapered surfaces 84, 86. In one embodiment, the remainder of the distal edge 70 and lateral edge 72 are dull or rounded. In one embodiment, the tip 78 proximate to the distal-most end 76 is curved slightly inwards, as indicated generally by the arrow 88 in FIG. 5 and arrow 88 (pointed perpendicular and into the plane of the paper) in FIG. 9, relative to the adjacent curvature of the blade 34.

In modified embodiments, suitable cutting edges may be provided on selected portions of one or more selected blade edges 68, 70, 72, 74 with efficacy, as needed or desired, giving due consideration to the goals of providing suitable cutting means on the stent 30 for effectively cutting through the trabecular meshwork 21 (FIG. 3) and/or of achieving one or more of the benefits and advantages as taught or suggested herein.

Referring in particular to FIG. 9, in one embodiment, the ratio between the lengths of the cutting edges 80, 82 is about 2:1. In another embodiment, the ratio between the lengths of the cutting edges 80, 82 is about 1:1. In yet another embodiment, the ratio between the lengths of the cutting edges 80, 82 is about 1:2. In modified embodiments, the lengths of the cutting edges 80, 82 may be efficaciously selected in other manners, as required or desired, giving due consideration to the goals of providing suitable cutting means on the stent 30 for effectively cutting through the trabecular meshwork 21 (FIG. 3) and/or of achieving one or more of the benefits and advantages as taught or suggested herein.

Still referring in particular to FIG. 9, in one embodiment, the ratio between the lengths of the cutting edges 80, 82 is in the range from about 2:1 to about 1:2. In another embodiment, the ratio between the lengths of the cutting edges 80, 82 is in the range from about 5:1 to about 1:5. In yet another embodiment, the ratio between the lengths of the cutting edges 80, 82 is in the range from about 10:1 to about 1:10. In modified embodiments, the lengths of the cutting edges 80, 82 may be efficaciously selected in other manners, as required or desired, giving due consideration to the goals of providing suitable cutting means on the stent 30 for effectively cutting through the trabecular meshwork 21 (FIG. 3) and/or of achieving one or more of the benefits and advantages as taught or suggested herein.

As shown in the top view of FIG. 9, the cutting edge 80 (and/or the distal end 70) and the cutting edge 82 (and/or the lateral edge 72) intersect at an angle θ. Stated differently, θ is the angle between the projections of the cutting edge 80 (and/or the distal end 70) and the cutting edge 82 (and/or the lateral edge 72) on a common plane which is not perpendicular to either of these edges.

Referring to in particular to FIG. 9, in one embodiment, the angle θ is about 50°. In another embodiment, the angle θ is in the range from about 40° to about 60°. In yet another embodiment, the angle θ is in the range from about 30° to about 70°. In modified embodiments, the angle θ may be efficaciously selected in other manners, as required or desired, giving due consideration to the goals of providing suitable cutting means on the stent 30 for effectively cutting through the trabecular meshwork 21 (FIG. 3) and/or of achieving one or more of the benefits and advantages as taught or suggested herein.

The stent 30 of the embodiments disclosed herein can be dimensioned in a wide variety of manners. Referring in particular to FIG. 3, the depth of Schlemm's canal 22 is typically about less than 400 microns (μm). Accordingly, the stent blade 34 is dimensioned so that the height of the blade 34 (referred to as H₄₁in FIG. 4) is typically less than about 400 μm. The snorkel shank 40 is dimensioned so that it has a length (referred to as L₄₁in FIG. 4) typically in the range from about 100 μm to about 300 μm which is roughly the typical range of the thickness of the trabecular meshwork 21.

Of course, as the skilled artisan will appreciate, that with the stent 30 implanted, the blade 34 may rest at any suitable position within Schlemm's canal 22. For example, the blade 34 may be adjacent to a front wall 90 of Schlemm's canal 22 (as shown in FIG. 3), or adjacent to a back wall 92 of Schlemm's canal 22, or at some intermediate location therebetween, as needed or desired. Also, the snorkel shank 40 may extend into Schlemm's canal 22. The length of the snorkel shank 40 and/or the dimensions of the blade 34 may be efficaciously adjusted to achieve the desired implant positioning.

The trabecular stenting device 30 (FIGS. 3-9) of the exemplary embodiment may be manufactured or fabricated by a wide variety of techniques. These include, without limitation, by molding, thermo-forming, or other micro-machining techniques, among other suitable techniques.

The trabecular stenting device 30 preferably comprises a biocompatible material such that inflammation arising due to irritation between the outer surface of the device 30 and the surrounding tissue is minimized. Biocompatible materials which may be used for the device 30 preferably include, but are not limited to, titanium, titanium alloys, medical grade silicone, e.g., Silastic™, available from Dow Corning Corporation of Midland, Mich.; and polyurethane, e.g., Pellethane™, also available from Dow Corning Corporation.

In other embodiments, the stent device 30 may comprise other types of biocompatible material, such as, by way of example, polyvinyl alcohol, polyvinyl pyrolidone, collagen, heparinized collagen, polytetrafluoroethylene, expanded polytetrafluoroethylene, fluorinated polymer, fluorinated elastomer, flexible fused silica, polyolefin, polyester, polysilicon, and/or a mixture of the aforementioned biocompatible materials, and the like. In still other embodiments, composite biocompatible material may be used, wherein a surface material may be used in addition to one or more of the aforementioned materials. For example, such a surface material may include polytetrafluoroethylene (PTFE) (such as Teflon™), polyimide, hydrogel, heparin, therapeutic drugs (such as beta-adrenergic antagonists and other anti-glaucoma drugs, or antibiotics), and the like.

In an exemplary embodiment of the trabecular meshwork surgery, the patient is placed in the supine position, prepped, draped and anesthetized as necessary. In one embodiment, a small (less than about 1 mm) incision, which may be self-sealing is made through the cornea 12. The corneal incision can be made in a number of ways, for example, by using a micro-knife, among other tools.

An applicator or delivery apparatus is used to advance the glaucoma stent 30 through the corneal incision and to the trabecular meshwork 21. Some embodiments of such a delivery apparatus are disclosed in U.S. application Ser. No. 10/101,548, filed Mar. 18, 2002, entitled APPLICATOR AND METHODS FOR PLACING A TRABECULAR SHUNT FOR GLAUCOMA TREATMENT, published as U.S. Publication No. 2002/0133168 and now abandoned, and U.S. Provisional Application No. 60/276,609, filed Mar. 16, 2001, entitled APPLICATOR AND METHODS FOR PLACING A TRABECULAR SHUNT FOR GLAUCOMA TREATMENT, the entire contents of each one of which are hereby incorporated by reference herein. Some embodiments of a delivery apparatus are also discussed in further detail later herein. Gonioscopic, microscopic, or endoscopic guidance may be used during the trabecular meshwork surgery.

With the device 30 held by the delivery apparatus, the blade 34 of the self-trephining glaucoma stent device 30 is used to cut and/or displace the material of the trabecular meshwork 21. The snorkel shank 40 may also facilitate in removal of this material during implantation. The delivery apparatus is withdrawn once the device 30 has been implanted in the eye 10. As shown in FIG. 3, once proper implantation has been accomplished the snorkel seat 38 rests on a top surface 94 of the trabecular meshwork 21, the snorkel shank 40 extends through the cavity 50 (created by the device 30) in the trabecular meshwork 21, and the blade extends inside Schlemm's canal 22.

Advantageously, the embodiments of the self-trephining stent device of the invention allow for a “one-step” procedure to make an incision in the trabecular meshwork and to subsequently implant the stent in the proper orientation and alignment within the eye to allow outflow of aqueous from the anterior chamber through the stent and into Schlemm's canal to lower and/or balance the intraocular pressure (IOP). Desirably, this provides for a faster, safer, and less expensive surgical procedure.

Many complications can arise in trabecular meshwork surgeries, wherein a knife is first used to create an incision in the trabecular meshwork, followed by removal of the knife and subsequent installation of the stent. For instance, the knife may cause some bleeding which clouds up the surgical site. This may require more effort and time to clean the surgical site prior to placement of the stent. Moreover, this may cause the intraocular pressure (IOP) to rise. Thus, undesirably, such a multiple step procedure may demand crisis management which slows down the surgery, makes it less safe, and more expensive.

FIG. 14 is a simplified partial view of an eye 10 illustrating the implantation of a self-trephining glaucoma stent device 30a having features and advantages in accordance with one embodiment. The stent 30a is generally similar to the stent 30 of FIGS. 3-9 except that its snorkel 32a comprises a longer shank 40a which extends into Schlemm's canal 22 and a lumen 42a which bifurcates into two output channels 45a.

In the illustrated embodiment of FIG. 14, the shank 40a terminates at the blade 34. Aqueous flows from the anterior chamber 20 into the lumen 42a through an inlet port 54a (as generally indicated by arrow 58a). Aqueous then flows through the output channels 45a and out of respective outlet ports 56a and into Schlemm's canal 22 (as generally indicated by arrows 60a). The outlet channels 45a extend radially outwards in generally opposed directions and the outlet ports 56a are configured to face in the general direction of the stent longitudinal axis 36 so that they open into Schlemm's canal 22 and are in proper orientation to allow aqueous outflow into Schlemm's canal 22 for lowering and/or balancing the intraocular pressure (IOP). As indicated above, fiducial marks or indicia and/or predetermined shapes of the snorkel seat 38 allow for proper orientation of the blade 34 and also the output channels 45a and respective ports 56a within Schlemm's canal.

In the illustrated embodiment of FIG. 14, two outflow channels 45a are provided. In another embodiment, only one outflow channel 45a is provided. In yet another embodiment, more than two outflow channels 45a are provided. In modified embodiments, the lumen 42a may extend all the way through to the blade 34 and provide an outlet port as discussed above with reference to the embodiment of FIGS. 3-9.

FIG. 15 is a simplified partial view of an eye 10 illustrating the implantation of a self-trephining glaucoma stent device 30b having features and advantages in accordance with one embodiment. The stent 30b is generally similar to the stent 30 of FIGS. 3-9 except that its snorkel 32b comprises a longer shank 40b which extends into Schlemm's canal 22 and a lumen 42b which bifurcates into two output channels 45b.

In the illustrated embodiment of FIG. 15, the shank 40b extends through the blade 34. Aqueous flows from the anterior chamber 20 into the lumen 42b through an inlet port 54b (as generally indicated by arrow 58b). Aqueous then flows through the output channels 45b and out of respective outlet ports 56b and into Schlemm's canal 22 (as generally indicated by arrows 60b). The outlet channels 45b extend radially outwards in generally opposed directions and the outlet ports 56b are configured to face in the general direction of the stent longitudinal axis 36 so that they open into Schlemm's canal 22 and are in proper orientation to allow aqueous outflow into Schlemm's canal 22 for lowering and/or balancing the intraocular pressure (IOP). As indicated above, fiducial marks or indicia and/or predetermined shapes of the snorkel seat 38 allow for proper orientation of the blade 34 and also the output channels 45b and respective ports 56b within Schlemm's canal.

In the illustrated embodiment of FIG. 15, two outflow channels 45b are provided. In another embodiment, only one outflow channel 45b is provided. In yet another embodiment, more than two outflow channels 45b are provided. In modified embodiments, the lumen 42b may extend all the way through to the blade 34 and provide an outlet port as discussed above with reference to the embodiment of FIGS. 3-9.

FIGS. 16-20 show different views of a self-trephining glaucoma stent device 30c having features and advantages in accordance with one embodiment. The stent 30c is generally similar to the stent 30 of FIGS. 3-9 except that it has a modified blade configuration. The stent 30c comprises a blade 34c which is a generally curved elongated sheet- or plate-like structure with an upper curved surface 62c and a lower curved surface 64c which defines a trough or open face channel 66c. The perimeter of the blade 34c is generally defined by a curved proximal edge 68c proximate to the snorkel 32, a curved distal edge 70c spaced from the proximal edge 68c by a pair of generally straight lateral edges 72c, 74c which are generally parallel to one another and have about the same length.

In the illustrated embodiment of FIGS. 16-20, the blade 34c comprises a cutting tip 78c. The cutting tip 78c preferably includes cutting edges formed on selected portions of the distal edge 70c and adjacent portions of the lateral edges 72c, 74c for cutting through the trabecular meshwork for placement of the snorkel 32. The cutting edges are sharp edges of beveled or tapered surfaces as discussed above in reference to FIG. 9. The embodiment of FIGS. 16-20 may be efficaciously modified to incorporate the snorkel configuration of the embodiments of FIGS. 14 and 15.

FIGS. 21-25 show different views of a self-trephining glaucoma stent device 30d having features and advantages in accordance with one embodiment. The stent 30d is generally similar to the stent 30 of FIGS. 3-9 except that it has a modified blade configuration. The stent 30d comprises a blade 34d which is a generally curved elongated sheet- or plate-like structure with an upper curved surface 62d and a lower curved surface 64d which defines a trough or open face channel 66d. The perimeter of the blade 34d is generally defined by a curved proximal edge 68d proximate to the snorkel 32, a pair of inwardly converging curved distal edges 70d′, 70d″ spaced from the proximal edge 68d by a pair of generally straight respective lateral edges 72d, 74d which are generally parallel to one another and have about the same length. The distal edges 70d′, 70d″ intersect at a distal-most point 76d of the blade 34d proximate a blade cutting tip 78d.

In the illustrated embodiment of FIGS. 21-25, the cutting tip 78d preferably includes cutting edges formed on the distal edges 70d′, 70d″ and extending from the distal-most point 76d of the blade 34d. In one embodiment, the cutting edges extend along only a portion of respective distal edges 70d′, 70d″. In another embodiment, the cutting edges extend along substantially the entire length of respective distal edges 70d′, 70d″. In yet another embodiment, at least portions of the lateral edges 72d, 74d proximate to respective distal edges 70d′, 70d″ have cutting edges. In a further embodiment, the tip 78d proximate to the distal-most end 76d is curved slightly inwards, as indicated generally by the arrow 88d in FIG. 21 and arrow 88d (pointed perpendicular and into the plane of the paper) in FIG. 22, relative to the adjacent curvature of the blade 34d.

In the embodiment of FIGS. 21-25, the cutting edges are sharp edges of beveled or tapered surfaces as discussed above in reference to FIG. 9. The embodiment of FIGS. 21-25 may be efficaciously modified to incorporate the snorkel configuration of the embodiments of FIGS. 14 and 15.

FIGS. 26-28 show different views of a self-trephining glaucoma stent device 30e having features and advantages in accordance with one embodiment. The stent device 30e generally comprises a snorkel 32e mechanically connected to or in mechanical communication with a blade or cutting tip 34e. The snorkel 32e has a seat, head or cap portion 38e mechanically connected to or in mechanical communication with a shank 40e, as discussed above. The shank 40e has a distal end or base 47e. The snorkel 32e further has a lumen 42e which bifurcates into a pair of outlet channels 45e, as discussed above in connection with FIGS. 14 and 15. Other lumen and inlet and outlet port configurations as taught or suggested herein may also be efficaciously used, as needed or desired.

In the illustrated embodiment of FIGS. 26-28, the blade 34e extends downwardly and outwardly from the shank distal end 47e. The blade 34e is angled relative to a generally longitudinal axis 43e of the snorkel 32e, as best seen in FIGS. 27 and 28. The blade 34e has a distal-most point 76e. The blade or cutting tip 34e has a pair of side edges 70e′, 70e″, including cutting edges, terminating at the distal-most point 76e, as best seen in FIG. 26. In one embodiment, the cutting edges are sharp edges of beveled or tapered surfaces as discussed above in reference to FIG. 9.

Referring to FIGS. 26-28, in one embodiment, the blade 34e includes cutting edges formed on the edges 70e′, 70e″ and extending from the distal-most point 76e of the blade 34d. In one embodiment, the cutting edges extend along only a portion of respective distal edges 70e′, 70e″. In another embodiment, the cutting edges extend along substantially the entire length of respective distal edges 70e′, 70e″. In yet another embodiment, the blade or cutting tip 34e comprises a bent tip of needle, for example, a 30 gauge needle.

In general, any of the blade configurations disclosed herein may be used in conjunction with any of the snorkel configurations disclosed herein or incorporated by reference herein to provide a self-trephining glaucoma stent device for making an incision in the trabecular meshwork for receiving the corresponding snorkel to provide a pathway for aqueous outflow from the eye anterior chamber to Schlemm's canal, thereby effectively lowering and/or balancing the intraocular pressure (IOP). The self-trephining ability of the device, advantageously, allows for a “one-step” procedure in which the incision and placement of the snorkel are accomplished by a single device and operation. In any of the embodiments, fiducial markings or indicia, and/or preselected configuration of the snorkel seat, and/or positioning of the stent device in a preloaded applicator may be used for proper orientation and alignment of the device during implantation.

Delivery Apparatus

In many cases, a surgeon works from a temporal incision when performing cataract or goniometry surgery. FIG. 29 illustrates a temporal implant procedure, wherein a delivery apparatus or “applicator” 100 having a curved tip 102 is used to deliver a stent 30 to a temporal side 27 of the eye 10. An incision 28 is made in the cornea 10, as discussed above. The apparatus 100 is then used to introduce the stent 30 through the incision 28 and implant it within the eye 10.

Still referring in particular to FIG. 29, in one embodiment, a similarly curved instrument would be used to make the incision through the trabecular meshwork 21. In other embodiments, a self-trephining stent device 30 may be used to make this incision through the trabecular meshwork 21, as discussed above. The temporal implantation procedure illustrated in FIG. 29 may be employed with the any of the various stent embodiments taught or suggested herein.

FIG. 30 illustrates one embodiment of an apparatus comprising an articulating stent applicator or retrieval device 100a. In this embodiment, a proximal arm 106 is attached to a distal arm 108 at a joint 112. This joint 112 is movable such that an angle formed between the proximal arm 106 and the distal arm 108 can change. One or more claws 114 can extend from the distal arm 108, in the case of a stent retrieval device. Similarly, this articulation mechanism may be used for the trabecular stent applicator, and thus the articulating applicator or retrieval device 100a may be either an applicator for the trabecular stent, a retrieval device, or both, in various embodiments. The embodiment of FIG. 30 may be employed with the any of the various stent embodiments taught or suggested herein.

FIG. 31 shows another illustrative method for placing any of the various stent embodiments taught or suggested herein at the implant site within the eye 10. A delivery apparatus 100b generally comprises a syringe portion 116 and a cannula portion 118. The distal section of the cannula 118 has at least one irrigating hole 120 and a distal space 122 for holding the stent device 30. The proximal end 124 of the lumen of the distal space 122 is sealed from the remaining lumen of the cannula portion 118. The delivery apparatus of FIG. 31 may be employed with the any of the various stent embodiments taught or suggested herein.

FIG. 48 illustrates one embodiment of the trabecular shunt applicator 502, holding the trabecular shunt 510 in place. Additionally, a trabecular meshwork blade 528 extends from the distal end of the applicator 502. In this embodiment, the blade 528 may be extended by spring action from the distal end of the applicator 502 when the operator pushes a button 530 or similarly actuates extension of the blade 528. The blade 528 can be retracted within the applicator 502 by means of a slide button 538, which the operator can move proximally to retract the blade 528. Alternatively, a plunger 532 may move the blade 528 forward and backward within the applicator 502. Also shown is the outer tube 534 of the applicator 502, as well as holes 536 in the applicator 502. These holes 536 may be used for aspiration or irrigation of the anterior chamber of the eye during the performance of trabecular meshwork surgery.

FIG. 49A shows one embodiment of a trabecular meshwork trephine, or punch 542. An inner tube 506 resides within an outer tube 504. The inner tube 506 is in communication with an inner plunger 546. The proximal end 550 of the inner plunger 546 is acted upon by a hammer 552 that is attached to a spring 548. The spring 548 may be recoiled or loaded, storing potential energy, and the hammer 552 is then held in place by an actuator 554 or other similar member in communication with the actuator 554. When the actuator 554 is acted upon by an operator, the spring 548 releases its potential energy, causing the hammer 552 to move forward, contacting the proximal end 550 of the inner plunger 546. This in turn causes the punch 544 to move forward, contacting the trabecular meshwork.

FIG. 49B view is a close-up, cross-sectional view of the punch 544. Again seen as the outer tube 504, the inner tube 506, and the punch 544 of the device. This trephine or punch may comprise a circular blade 556 or other similar configuration known to those skilled in the art for making a cut or punch hole in the trabecular meshwork of an eye.

FIGS. 50A and 50B illustrate embodiments of a control arm 598 which is attached to a mechanism for performing trabeculotomy. In FIG. 50A, a blade 570 extends from an end of the control arm 598. In some embodiments, the long axis of the control arm 598 runs parallel or semiparallel to the long axis of the applicator 502. The blade 570 may be used to make a trabeculotomy in preparation for placing the trabecular shunt 510 through the trabecular meshwork and into Schlemm's canal.

FIG. 50B shows a “hot tip” 571 at the end of the control arm 598. This hot tip 571 may be a cautery, laser, or other energy transfer device for making a hole in the trabecular meshwork in preparation for placing the shunt 510 through the trabecular meshwork and into Schlemm's canal.

FIGS. 51A through 51C illustrate various embodiments of devices, such as trephines, that can punch holes in the trabecular meshwork. In FIG. 51A, a trabecular meshwork punch 560 is illustrated. This punch 560 can make holes 561 in the trabecular meshwork 595. These holes 561 can be of various configurations, depending on the shape of the distal blade of the trabecular meshwork punch 560.

In FIG. 51B, a blade 566 extends from the end of a trabecular meshwork cutter 565. This blade 566 can make various punch holes 567 in the trabecular meshwork 595, as illustrated.

FIG. 51C illustrates a trabecular meshwork drill 568. The drill 568 has a distal drill bit 569, which can make a drill hole 561 in the trabecular meshwork 595.

In some embodiments, the holder comprises a clamp. In some embodiments, the apparatus further comprises a spring within the handpiece that is configured to be loaded when the stent is being held by the holder, the spring being at least partially unloaded upon actuating the actuator, allowing for release of the stent from the holder.

In various embodiments, the clamp comprises a plurality of claws configured to exert a clamping force onto the inlet section of the stent. The holder may also comprise a plurality of flanges.

In some embodiments, the distal portion of the elongate tip is made of a flexible material. This can be a flexible wire. The distal portion can have a deflection range, preferably of about 45 degrees from the long axis of the handpiece.

The delivery apparatus can further comprise an irrigation port in the elongate tip.

Some aspects include a method of placing a trabecular stent through a trabecular meshwork of an eye, the stent having an inlet section and an outlet section, including advancing a delivery apparatus holding the trabecular stent through an anterior chamber of the eye and into the trabecular meshwork, placing part of the stent through the trabecular meshwork and into a Schlemm's canal of the eye; and releasing the stent from the delivery apparatus.

In various embodiments, the method includes using a delivery apparatus that comprises a handpiece having a distal end and a proximal end; an elongate tip connected to the distal end of the handpiece, the elongate tip having a distal portion and being configured to be placed through a corneal incision and into an anterior chamber of the eye; a holder attached to the distal portion of the elongate tip, the holder configured to hold and release the inlet section of the trabecular stent; and an actuator on the handpiece that actuates the holder to release the inlet section of the trabecular stent from the holder.

In one aspect, the trabecular stent is removably attached to a delivery apparatus (also known as “applicator”). When the trabecular stent is deployed from the delivery apparatus into the eye, the outlet section is positioned in substantially opposite directions inside Schlemm's canal. In one embodiment, a deployment mechanism within the delivery apparatus includes a push-pull type plunger. In some embodiments, the delivery applicator may be a guidewire, an expandable basket, an inflatable balloon, or the like.

OTHER EMBODIMENTS

Screw/Barb Anchored Stent:

FIGS. 32 and 33 illustrate a glaucoma stent device 30f having features and advantages in accordance with one embodiment. This embodiment of the trabecular stent 30f includes a barbed or threaded screw-like extension or pin 126 with barbs 128 for anchoring. The barbed pin 126 extends from a distal or base portion 130 of the stent 30f.

In use, the stent 30f (FIG. 32) is advanced through the trabecular meshwork 21 and across Schlemm's canal 22. The barbed (or threaded) extension 126 penetrates into the back wall 92 of Schlemm's canal 22 up to the shoulder or base 130 that then rests on the back wall 92 of the canal 22. The combination of a shoulder 130 and a barbed pin 126 of a particular length limits the penetration depth of the barbed pin 126 to a predetermined or preselected distance. In one embodiment, the length of the pin 126 is about 0.5 mm or less. Advantageously, this barbed configuration provides a secure anchoring of the stent 30f. As discussed above, correct orientation of the stent 30f is ensured by appropriate fiducial marks, indicia or the like and by positioning of the stent in a preloaded applicator.

Referring to FIG. 32, the aqueous flows from the anterior chamber 20, through the lumen 42f, then out through two side-ports 56f to be directed in both directions along Schlemm's canal 22. Alternatively, flow could be directed in only one direction through a single side-port 56f. In other embodiments, more than two outlet ports 56f, for example, six to eight ports (like a pin wheel configuration), may be efficaciously used, as needed or desired.

Still referring to FIG. 32, in one embodiment, the stent 30f is inserted through a previously made incision in the trabecular meshwork 21. In other embodiments, the stent 30f may be combined with any of the blade configurations taught or suggested herein to provide self-trephining capability. In these cases, the incision through the trabecular meshwork 21 is made by the self-trephining stent device which has a blade at its base or proximate to the base.

Deeply Threaded Stent:

FIG. 34 illustrates a glaucoma stent device 30g having features and advantages in accordance with one embodiment. The stent 30g has a head or seat 38g and a shank or main body portion 40g with a base or distal end 132. This embodiment of the trabecular stent 30g includes a deep thread 134 (with threads 136) on the main body 40g of the stent 30g below the head 38g. The threads may or may not extend all the way to the base 132.

In use, the stent 30g (FIG. 34) is advanced through the meshwork 21 through a rotating motion, as with a conventional screw. Advantageously, the deep threads 136 provide retention and stabilization of the stent 30g in the trabecular meshwork 21.

Referring to FIG. 34, the aqueous flows from the anterior chamber 20, through the lumen 42g, then out through two side-ports 56g to be directed in both directions along Schlemm's canal 22. Alternatively, flow could be directed in only one direction through a single side-port 56g. In other embodiments, more than two outlet ports 56g may be efficaciously used, as needed or desired.

One suitable applicator or delivery apparatus for this stent 30g (FIG. 34) includes a preset rotation, for example, via a wound torsion spring or the like. The rotation is initiated by a release trigger on the applicator. A final twist of the applicator by the surgeon and observation of suitable fiducial marks, indicia or the like ensure proper alignment of the side ports 56g with Schlemm's canal 22.

Referring to FIG. 34, in one embodiment, the stent 30g is inserted through a previously made incision in the trabecular meshwork 21. In other embodiments, the stent 30g may be combined with any of the blade configurations taught or suggested herein to provide self-trephining capability. In these cases, the incision through the trabecular meshwork 21 is made by the self-trephining stent device which has a blade at its base or proximate to the base.

Rivet Style Stent:

FIG. 35 illustrates a glaucoma stent device 30h having features and advantages in accordance with one embodiment. The stent has a base or distal end 138. This embodiment of the trabecular stent 30h has a pair of flexible ribs 140. In the unused state, the ribs are initially generally straight (that is, extend in the general direction of arrow 142).

Referring to FIG. 35, upon insertion of the stent 30h through the trabecular meshwork 21, the ends 144 of respective ribs 140 of the stent 30h come to rest on the back wall 92 of Schlemm's canal 22. Further advancement of the stent 30h causes the ribs 140 to deform to the bent shape as shown in the drawing of FIG. 35. The ribs 140 are designed to first buckle near the base 138 of the stent 30h. Then the buckling point moves up the ribs 140 as the shank part 40h of the stent 30h is further advanced through the trabecular meshwork 21.

The lumen 42h (FIG. 35) in the stent 30h is a simple straight hole. The aqueous flows from the anterior chamber 20, through the lumen 42h, then out around the ribs 140 to the collector channels further along Schlemm's canal 22 in either direction.

Referring to FIG. 35, in one embodiment, the stent 30h is inserted through a previously made incision in the trabecular meshwork 21. In other embodiments, the stent 30h may be combined with any of the blade configurations taught or suggested herein to provide self-trephining capability. In these cases, the incision through the trabecular meshwork 21 is made by the self-trephining stent device which has a blade at its base or proximate to the base.

Grommet Style Stent:

FIG. 36 illustrates a glaucoma stent device 30i having features and advantages in accordance with one embodiment. This embodiment of the trabecular stent 30i includes a head or seat 38i, a tapered base portion 146 and an intermediate narrower waist portion or shank 40i.

In use, the stent 30i (FIG. 36) is advanced through the trabecular meshwork 21 and the base 146 is pushed into Schlemm's canal 22. The stent 30i is pushed slightly further, if necessary, until the meshwork 21 stretched by the tapered base 146 relaxes back and then contracts to engage the smaller diameter portion waist 40i of the stent 30i. Advantageously, the combination of the larger diameter head or seat 38i and base 146 of the stent 30i constrains undesirable stent movement. As discussed above, correct orientation of the stent 30i is ensured by appropriate fiducial marks, indicia or the like and by positioning of the stent in a preloaded applicator.

Referring to FIG. 36, the aqueous flows from the anterior chamber 20, through the lumen 42i, then out through two side-ports 56i to be directed in both directions along Schlemm's canal 22. Alternatively, flow could be directed in only one direction through a single side-port 56i. In other embodiments, more than two outlet ports 56i may be efficaciously used, as needed or desired.

Still referring to FIG. 36, in one embodiment, the stent 30i is inserted through a previously made incision in the trabecular meshwork 21. In other embodiments, the stent 30i may be combined with any of the blade configurations taught or suggested herein to provide self-trephining capability. In these cases, the incision through the trabecular meshwork 21 is made by the self-trephining stent device which has a blade at its base or proximate to the base.

Biointeractive Stent:

FIG. 37 illustrates a glaucoma stent device 30j having features and advantages in accordance with one embodiment. This embodiment of the trabecular stent 30j utilizes a region of biointeractive material 148 that provides a site for the trabecular meshwork 21 to firmly grip the stent 30j by ingrowth of the tissue into the biointeractive material 148. As shown in FIG. 37, preferably the biointeractive layer 148 is applied to those surfaces of the stent 30j which would abut against or come in contact with the trabecular meshwork 21.

In one embodiment, the biointeractive layer 148 (FIG. 37) may be a region of enhanced porosity with a growth promoting chemical. In one embodiment, a type of bio-glue 150 that dissolves over time is used to hold the stent secure during the time between insertion and sufficient ingrowth for stabilization. As discussed above, correct orientation of the stent 30j is ensured by appropriate fiducial marks, indicia or the like and by positioning of the stent in a preloaded applicator.

Referring to FIG. 37, the aqueous flows from the anterior chamber 20, through the lumen 42j, then out through two side-ports 56j to be directed in both directions along Schlemm's canal 22. Alternatively, flow could be directed in only one direction through a single side-port 56j. In other embodiments, more than two outlet ports 56j may be efficaciously used, as needed or desired.

Still referring to FIG. 37, in one embodiment, the stent 30j is inserted through a previously made incision in the trabecular meshwork 21. In other embodiments, the stent 30j may be combined with any of the blade configurations taught or suggested herein to provide self-trephining capability. In these cases, the incision through the trabecular meshwork 21 is made by the self-trephining stent device which has a blade at its base or proximate to the base.

Glued or Welded Stent:

FIG. 38 illustrates a glaucoma stent device 30k having features and advantages in accordance with one embodiment. This embodiment of the trabecular stent 30k is secured in place by using a permanent (non-dissolving) bio-glue 152 or a “welding” process (e.g. heat) to form a weld 152. The stent 30k has a head or seat 38k and a lower surface 46k.

The stent 30k is advanced through the trabecular meshwork 21 until the head or seat 38k comes to rest on the trabecular meshwork 21, that is, the head lower surface 46k abuts against the trabecular meshwork 21, and the glue or weld 152 is applied or formed therebetween, as shown in FIG. 38. As discussed above, correct orientation of the stent 30k is ensured by appropriate fiducial marks, indicia or the like and by positioning of the stent in a preloaded applicator.

Referring to FIG. 38, the aqueous flows from the anterior chamber 20, through the lumen 42k, then out through two side-ports 56k to be directed in both directions along Schlemm's canal 22. Alternatively, flow could be directed in only one direction through a single side-port 56k. In other embodiments, more than two outlet ports 56k may be efficaciously used, as needed or desired.

Still referring to FIG. 38, in one embodiment, the stent 30k is inserted through a previously made incision in the trabecular meshwork 21. In other embodiments, the stent 30k may be combined with any of the blade configurations taught or suggested herein to provide self-trephining capability. In these cases, the incision through the trabecular meshwork 21 is made by the self-trephining stent device which has a blade at its base or proximate to the base.

Hydrophilic Latching Stent:

FIG. 39 illustrates a glaucoma stent device 30m having features and advantages in accordance with one embodiment. This embodiment of the trabecular stent 30m is fabricated from a hydrophilic material that expands with absorption of water. Desirably, this would enable the device 30m to be inserted through a smaller incision in the trabecular meshwork 21. The subsequent expansion (illustrated by the smaller arrows 154) of the stent 30m would advantageously enable it to latch in place in the trabecular meshwork 21. As discussed above, correct orientation of the stent 30m is ensured by appropriate fiducial marks, indicia or the like and by positioning of the stent in a preloaded applicator.

Referring to FIG. 39, the aqueous flows from the anterior chamber 20, through the lumen 42m, then out through two side-ports 56m to be directed in both directions along Schlemm's canal 22. Alternatively, flow could be directed in only one direction through a single side-port 56m. In other embodiments, more than two outlet ports 56m may be efficaciously used, as needed or desired.

Still referring to FIG. 39, in one embodiment, the stent 30m is inserted through a previously made incision in the trabecular meshwork 21. In other embodiments, the stent 30m may be combined with any of the blade configurations taught or suggested herein to provide self-trephining capability. In these cases, the incision through the trabecular meshwork 21 is made by the self-trephining stent device which has a blade at its base or proximate to the base.

Photodynamic Stent:

FIG. 40 illustrates a glaucoma stent device 30n having features and advantages in accordance with one embodiment. This embodiment of the trabecular stent 30n is fabricated from a photodynamic material that expands on exposure to light.

It is commonly known that there is a diurnal variation in the aqueous humor production by the eye—it is higher during the day than it is at night. The lumen 42n of the stent 30n responds to light entering the cornea during the day by expanding and allowing higher flow of aqueous through the lumen 42n and into Schlemm's canal 22. This expansion is generally indicated by the smaller arrows 156 (FIG. 40) which show the lumen 42n (and ports) expanding or opening in response to light stimulus. (The light or radiation energy E is generally given by E=hv, where h is Planck's constant and v is the frequency.) At night, in darkness, the lumen diameter decreases and reduces the flow allowed through the lumen 42n. In one embodiment, an excitation wavelength that is different from that commonly encountered is provided on an as-needed basis to provide higher flow of aqueous to Schlemm's canal 22.

This photodynamic implementation is shown in FIG. 40 for the self-latching style of stent 30n, but can be efficaciously used with any of the other stent embodiments, as needed or desired. As discussed above, correct orientation of the stent 30n is ensured by appropriate fiducial marks, indicia or the like and by positioning of the stent in a preloaded applicator.

Referring to FIG. 40, the aqueous flows from the anterior chamber 20, through the lumen 42n, then out through two side-ports 56n to be directed in both directions along Schlemm's canal 22. Alternatively, flow could be directed in only one direction through a single side-port 56n. In other embodiments, more than two outlet ports 56n may be efficaciously used, as needed or desired.

Still referring to FIG. 40, in one embodiment, the stent 30n is inserted through a previously made incision in the trabecular meshwork 21. In other embodiments, the stent 30n may be combined with any of the blade configurations taught or suggested herein to provide self-trephining capability. In these cases, the incision through the trabecular meshwork 21 is made by the self-trephining stent device which has a blade at its base or proximate to the base.

Collector Channel Alignment Stent:

FIG. 41 illustrates a glaucoma stent device 30p having features and advantages in accordance with one embodiment. This figure depicts an embodiment of a stent 30p that directs aqueous from the anterior chamber 20 directly into a collector channel 29 which empties into aqueous veins. The stent 30p has a base or distal end 160.

In the illustrated embodiment of FIG. 41, a removable alignment pin 158 is utilized to align the stent lumen 42p with the collector channel 29. In use, the pin 158 extends through the stent lumen 42p and protrudes through the base 160 and extends into the collector channel 29 to center and/or align the stent 30p over the collector channel 29. The stent 30p is then pressed firmly against the back wall 92 of Schlemm's canal 22. A permanent bio-glue 162 is used between the stent base and the back wall 92 of Schlemm's canal 22 to seat and securely hold the stent 30p in place. Once positioned, the pin 158 is withdrawn from the lumen 42p to allow the aqueous to flow directly from the anterior chamber 20 into the collector duct 29. The collector ducts are nominally 20 to 100 micrometers (μm) in diameter and are visualized with a suitable microscopy method (such as ultrasound biomicroscopy (UBM)) or laser imaging to provide guidance for placement of the stent 30p.

Referring to FIG. 41, in one embodiment, the stent 30p is inserted through a previously made incision in the trabecular meshwork 21. In other embodiments, the stent 30p may be combined with any of the blade configurations taught or suggested herein to provide self-trephining capability. In these cases, the incision through the trabecular meshwork 21 is made by the self-trephining stent device which has a blade at its base or proximate to the base.

Barbed Stent (Anterior Chamber to Collector Channel):

FIG. 42 illustrates a glaucoma stent device 30q having features and advantages in accordance with one embodiment. This figure depicts an embodiment of a stent 30q that directs aqueous from the anterior chamber 20 directly into a collector channel 29 which empties into aqueous veins. The stent 30q has a base or distal end 166 and the channel 29 has wall(s) 164.

In the illustrated embodiment of FIG. 42, a barbed, small-diameter extension or pin 168 on the stent base 166 is guided into the collector channel 29 and anchors on the wall(s) 164 of the channel 29. The pin 168 has barbs 170 which advantageously provide anchoring of the stent 30q. The collector ducts 29 are nominally 20 to 100 micrometers (μm) in diameter and are visualized with a suitable microscopy method (such as ultrasound biomicroscopy (UBM)) or laser imaging to provide guidance for placement of the stent.

Referring to FIG. 42, in one embodiment, the stent 30q is inserted through a previously made incision in the trabecular meshwork 21. In other embodiments, the stent 30q may be combined with any of the blade configurations taught or suggested herein to provide self-trephining capability. In these cases, the incision through the trabecular meshwork 21 is made by the self-trephining stent device which has a blade at its base or proximate to the base.

Valved Tube Stent (Anterior Chamber to Choroid):

FIG. 43 illustrates a valved tube stent device 30r having features and advantages in accordance with one embodiment. This is an embodiment of a stent 30r that provides a channel for flow between the anterior chamber 20 and the highly vascular choroid 17. Clinically, the choroid 17 can be at pressures lower than those desired for the eye 10. Therefore, this stent 30r includes a valve with an opening pressure equal to the desired pressure difference between the choroid 17 and the anterior chamber 20 or a constriction that provide the desired pressure drop.

Osmotic Membrane (Anterior Chamber to Choroid):

FIG. 44 illustrates an osmotic membrane device 30s having features and advantages in accordance with one embodiment. This embodiment provides a channel for flow between the anterior chamber 20 and the highly vascular choroid 17. The osmotic membrane 30s is used to replace a portion of the endothelial layer of the choroid 17. Since the choroid 17 is highly vascular with blood vessels, the concentration of water on the choroid side is lower than in the anterior chamber 20 of the eye 10. Therefore, the osmotic gradient drives water from the anterior chamber 20 into the choroid 17.

Clinically, the choroid 17 (FIG. 44) can be at pressures lower than those desired for the eye 10. Therefore, desirably, both osmotic pressure and the physical pressure gradient are in favor of flow into the choroid 17. Flow control is provided by proper sizing of the area of the membrane, —the larger the membrane area is the larger the flow rate will be. This advantageously enables tailoring to tune the flow to the desired physiological rates.

Ab Externo Insertion of Stent Via Small Puncture:

FIG. 45 illustrates the implantation of a stent 30t using an ab externo procedure having features and advantages in accordance with one embodiment. In the ab externo procedure of FIG. 45, the stent 30t is inserted into Schlemm's canal 21 with the aid of an applicator or delivery apparatus 100c that creates a small puncture into the eye 10 from outside.

Referring to FIG. 45, the stent 30t is housed in the applicator 100c, and pushed out of the applicator 100c once the applicator tip is in position within the trabecular meshwork 21. Since the tissue surrounding the trabecular meshwork 21 is optically opaque, an imaging technique, such as ultrasound biomicroscopy (UBM) or a laser imaging technique, is utilized. The imaging provides guidance for the insertion of the applicator tip and the deployment of the stent 30t. This technique can be used with a large variety of stent embodiments with slight modifications since the trabecular meshwork 21 is punctured from the scleral side rather than the anterior chamber side in the ab externo insertion.

FIG. 46 a glaucoma stent device 30u having features and advantages in accordance with a modified embodiment. This grommet-style stent 30u for ab externo insertion is a modification of the embodiment of FIG. 36. In the embodiment of FIG. 46, the upper part or head 38u is tapered while the lower part or base 172 is flat, as opposed to the embodiment of FIG. 36. The stent 30u is inserted from the outside of the eye 10 through a puncture in the sclera. Many of the other embodiments of stents taught or suggested herein can be modified for similar implantation.

This ultra-microscopic device 30u (FIG. 46) can be used with (1) a targeting Lasik-type laser, or with (2) contact on eyes or with (3) combined ultrasound microscope or (4) other device insertor handpiece.

Targeted Drug Delivery to the Trabecular Meshwork:

FIG. 47 illustrates a targeted drug delivery implant 30v having features and advantages in accordance with one embodiment. This drawing is a depiction of a targeted drug delivery concept. The slow release implant 30v is implanted within the trabecular meshwork 21.

A drug that is designed to target the trabecular meshwork 21 to increase its porosity, or improve the active transport across the endothelial layer of Schlemm's canal 22 can be stored in this small implant 30v (FIG. 47). Advantageously, slow release of the drug promotes the desired physiology at minimal dosage levels since the drug is released into the very structure that it is designed to modify.

While the components and techniques of the invention have been described with a certain degree of particularity, it is manifest that many changes may be made in the specific designs, constructions and methodology herein above described without departing from the spirit and scope of this disclosure. It should be understood that the invention is not limited to the embodiments set forth herein for purposes of exemplification, but is to be defined only by a fair reading of the appended claims, including the full range of equivalency to which each element thereof is entitled.

Additional Disclosure

- Other ways to close a valve other than pressure: concentration, expansion/contraction, pH
- Bypass directly to collector channels
  - hollow dart
  - pin guided tube welded or glued into place
  - Stent to conjunctival space using a sterile filter for bacterial backflow/infection prevention
- Subchoroidal shunt with valve to prevent hypotony
- Use high salt concentrations (osmotic pump) to drive liquid through trabecular meshwork.
- + add drug to liquid going through to coat/repair cells.
- Another ab-externo approach wherein a sighting mechanism, such as ultrasonic and/or ultrabiomicroscope is used to locate Schlemm's canal in space, and drive an HTS type device through the external wall of Schlemm's and into the trabecular meshwork. Device could unfold so incision can be smaller in sclera/external Schlemm's than in internal Schlemm's wall. Sleeve/pushrod approach. Could be very short and uninvasive procedure requiring very little skill, provided the sighting technology was well done. Should compensate for eye movement, as is done with Lasik. Seal Schlemm's external wall wound with bioglue or bioadhesive, if necessary.
- A device placed into anterior chamber for slow release of drug to treat/cure outflow pathway. Replace or recharge device once or twice per year.
- Photodynamic response valve to synchronize outflow rate with natural diurnal variations.
- Ab-interno-to-temporal HTS implantation.
- A device that expands for improved seating into place. Activated by liquid contact (swells to final shape), or body heat (eg, nitinol).
- Develop a permeability test to measure outflow capacity directly, and use to design treatment.
- Develop a glaucoma assay that uses near-IR, Raman scattering or visible light methods to sense biochemical signals that could lead to glaucoma: metabolites, cell apoptosis, oxygen levels, pH, degredation products, etc.

FIG. 52 shows a perspective view illustrating the seton implant 1031 of an embodiment of the present disclosure positioned within the tissue of an eye 10. A hole/opening is created through the diseased trabecular meshwork 21. The distal section of the seton implant 1031 is inserted into the hole/opening, wherein the inlet end is exposed to the anterior chamber 20 while the outlet end is positioned at about an exterior surface 1043 of said diseased trabecular meshwork 21. In a further embodiment, the outlet end may further enter into fluid collection channels of the existing outflow pathways.

In one embodiment, the means for forming a hole/opening in the trabecular mesh 21 may comprise an incision with a microknife, an incision by a pointed guidewire, a sharpened applicator, a screw shaped applicator, an irrigating applicator, or a barbed applicator. Alternatively, the trabecular meshwork may be dissected off with an instrument similar to a retinal pick or microcurrette. The opening may alternately be created by retrograde fiberoptic laser ablation.

FIG. 53 shows an illustrative method for placing a seton implant at the implant site. An irrigating knife or applicator 1051 comprises a syringe portion 1054 and a cannula portion 1055. The distal section of the cannula portion 1055 has at least one irrigating hole 1053 and a distal space 1056 for holding a seton implant 1031. The proximal end 1057 of the lumen of the distal space 1056 is sealed from the remaining lumen of the cannula portion 1055.

For positioning the seton 1031 in the hole or opening through the trabecular meshwork, the seton may be advanced over the guidewire or a fiberoptic (retrograde). In another embodiment, the seton is directly placed on the delivery applicator and advanced to the implant site, wherein the delivery applicator holds the seton securely during the delivery stage and releases it during the deployment stage.

In an exemplary embodiment of the trabecular meshwork surgery, the patient is placed in the supine position, prepped, draped and anesthesia obtained. In one embodiment, a small (less than 1 mm) self sealing incision is made. Through the cornea opposite the seton placement site, an incision is made in trabecular meshwork with an irrigating knife. The seton 1031 is then advanced through the cornea incision 1052 across the anterior chamber 20 held in an irrigating applicator 1051 under gonioscopic (lens) or endoscopic guidance. The applicator is withdrawn and the surgery concluded. The irrigating knife may be within a size range of 20 to 40 gauges, preferably about 30 gauge.

FIG. 54 illustrates a cut/install tool 5410 configured to form an opening in eye tissue (e.g., a trabecular meshwork incision) and install an TOP relief device 5405. In the illustrated embodiment the device install tool 5410 is an elongate member having a bent tip. A portion of the device install tool may be configured to fit within a lumen of the TOP relief device 5405 to carry the TOP relief device 5405 as shown. In one embodiment, the device install tool 5410 is a needle (e.g. a 30-gauge needle).

Claims

1. A method of treating an ocular disorder comprising: forming an incision in a cornea or a corneal limbus of an eye to access an anterior chamber of the eye;introducing a shunt through the incision and into the anterior chamber of the eye using a delivery device;forming an opening in ocular tissue at an anterior chamber angle; andadvancing the shunt from within the anterior chamber of the eye using a curved distal end portion of the delivery device, with an outlet portion of the shunt leading an inlet portion of the shunt, through the opening to an implantation location wherein at least a portion of the shunt is positioned between a sclera and a ciliary body of the eye while the shunt resides entirely within the confines of the sclera and the cornea of the eye and wherein a proximal end of the shunt is configured to reside in the anterior chamber when in the implantation location,thereby facilitating draining of fluid from the anterior chamber such that fluid flows into an inlet port of the inlet portion and out through one or more outlet ports of the outlet portion.
2. The method of claim 1, wherein advancing the shunt involves positioning the shunt so that a first portion of the outer circumferential surface of the shunt is in contact with the ciliary body of the eye and so that a second portion of the outer circumferential surface of the shunt opposite the first portion is in contact with the sclera.
3. The method of claim 1, wherein forming the incision involves forming a self-sealing incision.
4. The method of claim 3, wherein forming the opening in ocular tissue is performed using the delivery device.
5. The method of claim 3 additionally comprising removing the shunt from the delivery device by moving an actuator on a handpiece of the delivery device.
6. The method of claim 1, wherein forming the opening in ocular tissue is performed using the delivery device.
7. The method of claim 1, additionally comprising removing the shunt from the delivery device by moving an actuator on a handpiece of the delivery device.
8. The method of claim 1, additionally comprising actuating an actuator on a handpiece of the delivery device to cause a loaded spring within the handpiece to at least partially unload, thereby deploying the shunt from the delivery device.
9. A method of treating an ocular disorder, the method comprising: inserting an implant into an anterior chamber of an eye, the implant comprising an elongated body made of biocompatible material that extends between a proximal end and a distal end of the implant, the proximal end comprising an inlet port and the distal end comprising an outlet port, and a lumen extending from the inlet port to the outlet port;advancing the implant from within the anterior chamber of an eye to an anterior chamber angle of the eye using a delivery device having a curved distal end portion; andpositioning the implant such that the proximal end of the implant resides within the anterior chamber and such that at least a portion of the implant, which is between the proximal end and the distal end of the implant, is in contact with a sclera and a ciliary body of the eye while the elongated body resides entirely within the confines of the sclera and a cornea of the eye,thereby facilitating drainage of aqueous humor out of the anterior chamber through the implant.
10. The method of claim 9, wherein said advancing the implant from within the anterior chamber of the eye to the anterior chamber angle of the eye comprises advancing the implant with the distal end leading the proximal end.
11. The method of claim 10, wherein said inserting the implant into the anterior chamber of the eye comprises inserting the implant through a self-sealing incision in the cornea.
12. The method of claim 11, wherein inserting the implant comprises inserting a tubular implant.
13. The method of claim 12, wherein said positioning the implant comprises positioning the implant so that a first portion of an outer circumferential surface of the implant is in contact with the ciliary body of the eye and so that a second portion of the outer circumferential surface of the implant is in contact with the sclera.
14. The method of claim 10, wherein inserting the implant comprises inserting a tubular implant.
15. The method of claim 14, wherein said positioning the implant comprises positioning the implant so that a first portion of an outer circumferential surface of the implant is in contact with the ciliary body of the eye and so that a second portion of the outer circumferential surface of the implant is in contact with the sclera.
16. The method of claim 10, additionally comprising removing the implant from the delivery device by moving an actuator on a handpiece of the delivery device.
17. The method of claim 9, additionally comprising actuating an actuator on a handpiece of the delivery device to cause a loaded spring within the handpiece to at least partially unload, thereby deploying the implant from the delivery device.
18. A system for shunting aqueous humor from an anterior chamber of a living human eye, the system comprising: an implant having an elongated body made of biocompatible material that extends between a proximal end and a distal end of the implant, at least a portion of the elongated body being implantable at a site between a sclera and a ciliary body of the eye while the elongated body resides entirely within the confines of the sclera and a cornea of the eye, the proximal end of the implant being configured to reside within an anterior chamber angle of the eye, and a lumen extending from at least one inlet port located at the proximal end of the implant, through at least a portion of the elongated body, and to one or more outlet ports located at or near the distal end of the implant so as to drain fluid from the anterior chamber of the eye; anda delivery device having an elongated member with a curved distal end portion, the implant being positionable on the elongated member with its one or more outlet ports disposed closer to a distal end of the elongated member than the at least one inlet port of the implant so as to advance the implant from within the anterior chamber to said site between the sclera and the ciliary body using an ab interno procedure.
19. The system of claim 18, wherein the delivery device is sized so as to fit through a self-sealing incision into the anterior chamber.
20. The system of claim 19, wherein the implant has a sufficient length such that the distal end of the implant contacts uveal tissue of the eye when implanted in the eye.
21. The system of claim 19, wherein the implant includes at least one anchor to inhibit movement of the implant once implanted with the portion of the elongated body located between the sclera and the ciliary body.
22. The system of claim 19, wherein the elongated member of the delivery device is pointed.
23. The system of claim 19, wherein the implant is configured such that when the proximal end of the implant is disposed within the anterior chamber of the eye, the distal end of the implant is in contact with the ciliary body.
24. The system of claim 19, wherein the one or more outlet ports drain into a uveoscleral outflow path of the eye.
25. The system of claim 19, wherein the delivery device comprises a spring within a handpiece of the delivery device, and wherein the spring is configured to be at least partially unloaded upon actuating an actuator on the handpiece, thereby allowing for release of the implant from the delivery device.
26. The system of claim 19, wherein the proximal end of the implant comprises a seat configured to facilitate stabilization of the implant.
27. The system of claim 26, wherein the seat is circular in shape.
28. The system of claim 19, wherein at least a portion of a length of the elongated body of the implant comprises retention members.
29. The system of claim 18, wherein the delivery device has a diameter sized to fit through an incision of 1 mm or less.
30. The system of claim 18, wherein the implant has a sufficient length such that the distal end of the implant contacts uveal tissue of the eye when implanted in the eye.
31. The system of claim 18, wherein the implant includes at least one anchor to inhibit movement of the implant once implanted with the portion of the elongated body located between the sclera and the ciliary body.
32. The system of claim 18, wherein the elongated member of the delivery device is pointed.
33. The system of claim 18, wherein the implant is configured such that when the proximal end of the implant is disposed within the anterior chamber of the eye, the distal end of the implant is in contact with the ciliary body.
34. The system of claim 18, wherein the one or more outlet ports drain into a uveoscleral outflow path of the eye.
35. The system of claim 18, wherein the proximal end of the implant comprises a seat configured to facilitate stabilization of the implant.
36. The system of claim 35, wherein the seat is circular in shape.
37. The system of claim 18, wherein at least a portion of a length of the elongated body of the implant comprises retention members.
38. The system of claim 18, wherein the delivery device comprises a spring within a handpiece of the delivery device, and wherein the spring is configured to be at least partially unloaded upon actuating an actuator on the handpiece, thereby allowing for release of the implant from the delivery device.

RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 13/301,648, filed Nov. 21, 2011, entitled OCULAR IMPLANT SYSTEMS, now U.S. Pat. No. 8,579,846, which is a continuation of U.S. patent application Ser. No. 12/366,508, filed Feb. 5, 2009, entitled SELF-TREPHINING IMPLANT AND METHODS THEREOF FOR TREATMENT OF OCULAR DISORDERS, now U.S. Pat. No. 8,062,244, which is a divisional of U.S. patent application Ser. No. 11/598,542, filed Nov. 13, 2006, entitled IMPLANT AND METHODS THEREOF FOR TREATMENT OF OCULAR DISORDERS, now U.S. Pat. No. 7,563,241, which is a continuation of U.S. patent application Ser. No. 10/118,578, filed Apr. 8, 2002, entitled GLAUCOMA STENT AND METHODS THEREOF FOR GLAUCOMA TREATMENT, now U.S. Pat. No. 7,135,009, which claims the benefit of U.S. Provisional Application No. 60/281,973, filed Apr. 7, 2001, entitled GLAUCOMA SHUNT AND METHODS THEREOF FOR GLAUCOMA TREATMENT, the entire contents of each of which are hereby incorporated by reference herein.

US Referenced Citations (774)

Number	Name	Date	Kind
2031754	Mills	Feb 1936	A
2127903	Bowen	Aug 1938	A
2269963	Frederick	Jan 1942	A
3159161	Ness	Dec 1964	A
3439675	Cohen	Apr 1969	A
3717151	Collett	Feb 1973	A
3788327	Donowitz et al.	Jan 1974	A
3827700	Kaller	Aug 1974	A
3863623	Trueblood et al.	Feb 1975	A
3915172	Krejci et al.	Oct 1975	A
3948271	Aklyama	Apr 1976	A
3948871	Butterfield et al.	Apr 1976	A
3976077	Kerfoot, Jr.	Aug 1976	A
4037604	Newkirk	Jul 1977	A
4043346	Mobley et al.	Aug 1977	A
4113088	Binkhorst	Sep 1978	A
4168697	Cantekin	Sep 1979	A
4175563	Arenberg et al.	Nov 1979	A
4299227	Lincoff	Nov 1981	A
4366582	Faulkner	Jan 1983	A
4402681	Haas et al.	Sep 1983	A
4428746	Mendez	Jan 1984	A
4449529	Burns et al.	May 1984	A
4449974	Messingschlager	May 1984	A
4457757	Molteno	Jul 1984	A
4501274	Skjaerpe	Feb 1985	A
4521210	Wong	Jun 1985	A
4554918	White	Nov 1985	A
4560383	Leiske	Dec 1985	A
4578058	Grandon	Mar 1986	A
4583224	Ishii et al.	Apr 1986	A
4604087	Joseph	Aug 1986	A
4632842	Karwoski et al.	Dec 1986	A
4634418	Binder	Jan 1987	A
4642090	Ultrata	Feb 1987	A
4692142	Dignam et al.	Sep 1987	A
4718907	Karwoski et al.	Jan 1988	A
4722724	Schocket	Feb 1988	A
4733665	Palmaz	Mar 1988	A
4750901	Molteno	Jun 1988	A
4787885	Binder	Nov 1988	A
4800870	Reid, Jr.	Jan 1989	A
4800890	Cramer	Jan 1989	A
4804382	Turina et al.	Feb 1989	A
4820626	Williams et al.	Apr 1989	A
4826478	Schocket	May 1989	A
4846172	Berlin	Jul 1989	A
4846793	Leonard et al.	Jul 1989	A
4853224	Wong	Aug 1989	A
4863457	Lee	Sep 1989	A
4867173	Leoni	Sep 1989	A
4870953	DonMicheal et al.	Oct 1989	A
4883864	Scholz	Nov 1989	A
4886488	White	Dec 1989	A
4900300	Lee	Feb 1990	A
4905667	Foerster et al.	Mar 1990	A
4936825	Ungerleider	Jun 1990	A
4946436	Smith	Aug 1990	A
4968296	Ritch et al.	Nov 1990	A
4986810	Semrad	Jan 1991	A
4991602	Amplatz et al.	Feb 1991	A
4997652	Wong	Mar 1991	A
5005577	Frenekl	Apr 1991	A
5041081	Odrich	Aug 1991	A
5053040	Goldsmith, III	Oct 1991	A
5053044	Mueller et al.	Oct 1991	A
5073163	Lippman	Dec 1991	A
5092837	Ritch et al.	Mar 1992	A
5095887	Leon et al.	Mar 1992	A
5116327	Seder et al.	May 1992	A
5127901	Odrich	Jul 1992	A
5129895	Vassiliadis et al.	Jul 1992	A
5139502	Berg et al.	Aug 1992	A
5164188	Wong	Nov 1992	A
5169386	Becker et al.	Dec 1992	A
5171213	Price, Jr.	Dec 1992	A
5178604	Baerveldt et al.	Jan 1993	A
5180362	Worst	Jan 1993	A
5207685	Cinberg et al.	May 1993	A
5221255	Mahurkar et al.	Jun 1993	A
5246451	Trescony et al.	Sep 1993	A
5248231	Denham et al.	Sep 1993	A
5284476	Kock	Feb 1994	A
5290295	Querals et al.	Mar 1994	A
5300020	L'Esperance, Jr.	Apr 1994	A
5318513	Leib et al.	Jun 1994	A
5324306	Makower et al.	Jun 1994	A
5334137	Freeman	Aug 1994	A
5338291	Speckman et al.	Aug 1994	A
5342370	Simon et al.	Aug 1994	A
5346464	Camras	Sep 1994	A
5358492	Feibus	Oct 1994	A
5360399	Stegmann	Nov 1994	A
5364374	Morrison et al.	Nov 1994	A
5370607	Memmen	Dec 1994	A
5370641	O'Donnell, Jr.	Dec 1994	A
5372577	Ungerleider	Dec 1994	A
5397300	Baerveldt et al.	Mar 1995	A
5409457	del Cerro et al.	Apr 1995	A
5415666	Gourlay et al.	May 1995	A
5433701	Rubinstein	Jul 1995	A
5443505	Wong et al.	Aug 1995	A
5445637	Bretton	Aug 1995	A
5454796	Krupin	Oct 1995	A
5462558	Kolesa et al.	Oct 1995	A
5472440	Beckman	Dec 1995	A
5476445	Baerveldt et al.	Dec 1995	A
5486165	Stegmann	Jan 1996	A
5502052	DeSantis	Mar 1996	A
5516522	Peyman et al.	May 1996	A
5520631	Nordquist et al.	May 1996	A
5547993	Miki	Aug 1996	A
5556400	Tunis	Sep 1996	A
5557453	Schalz et al.	Sep 1996	A
5558629	Baerveldt et al.	Sep 1996	A
5558630	Fisher	Sep 1996	A
5558637	Allonen et al.	Sep 1996	A
5562641	Flomenblit et al.	Oct 1996	A
RE35390	Smith	Dec 1996	E
5601094	Reiss	Feb 1997	A
5601549	Miyagi	Feb 1997	A
5626558	Suson	May 1997	A
5626559	Solomon	May 1997	A
5626588	Sauer et al.	May 1997	A
5639278	Dereume et al.	Jun 1997	A
5643321	McDevitt	Jul 1997	A
5651782	Simon et al.	Jul 1997	A
5651783	Reynard	Jul 1997	A
5652236	Krauss	Jul 1997	A
5653724	Imonti	Aug 1997	A
5663205	Ogawa et al.	Sep 1997	A
5665114	Weadock et al.	Sep 1997	A
5669501	Hissong et al.	Sep 1997	A
5670161	Healy et al.	Sep 1997	A
5676679	Simon et al.	Oct 1997	A
5681275	Ahmed	Oct 1997	A
5681323	Arick	Oct 1997	A
5695479	Jagpal	Dec 1997	A
5702414	Richter et al.	Dec 1997	A
5702419	Berry et al.	Dec 1997	A
5704907	Nordquist et al.	Jan 1998	A
5713844	Peyman	Feb 1998	A
5723005	Herrick	Mar 1998	A
5725529	Nicholson et al.	Mar 1998	A
5725546	Samson	Mar 1998	A
5733256	Costin	Mar 1998	A
5741292	Mendius	Apr 1998	A
5741333	Frid	Apr 1998	A
5743868	Brown et al.	Apr 1998	A
5752928	de Roulhac et al.	May 1998	A
5762625	Igaki	Jun 1998	A
5766242	Wong et al.	Jun 1998	A
5766243	Christensen et al.	Jun 1998	A
5767079	Glaser et al.	Jun 1998	A
5784147	Volk	Jul 1998	A
5785674	Mateen	Jul 1998	A
5792099	DeCamp et al.	Aug 1998	A
5800376	Vaskelis	Sep 1998	A
5807244	Barot	Sep 1998	A
5807302	Wandel	Sep 1998	A
5810870	Myers et al.	Sep 1998	A
5814620	Robinson et al.	Sep 1998	A
5817100	Igaki	Oct 1998	A
5824071	Nelson et al.	Oct 1998	A
5824072	Wong	Oct 1998	A
5830139	Abreu	Nov 1998	A
5830171	Wallace	Nov 1998	A
5833694	Poncet	Nov 1998	A
5836939	Negus et al.	Nov 1998	A
5840041	Petter et al.	Nov 1998	A
5865831	Cozean et al.	Feb 1999	A
5868697	Richter et al.	Feb 1999	A
5869468	Freeman	Feb 1999	A
5879319	Pynson et al.	Mar 1999	A
5882327	Jacob	Mar 1999	A
5886822	Spitzer	Mar 1999	A
5891084	Lee	Apr 1999	A
5893837	Eagles et al.	Apr 1999	A
5908449	Bruchman et al.	Jun 1999	A
5913852	Magram	Jun 1999	A
5925342	Adorante et al.	Jul 1999	A
5932299	Katoot	Aug 1999	A
5941250	Aramant et al.	Aug 1999	A
5952378	Stjerschantz et al.	Sep 1999	A
5968058	Richter et al.	Oct 1999	A
5980928	Terry	Nov 1999	A
5981598	Tatton	Nov 1999	A
5984913	Kritzinger et al.	Nov 1999	A
6004302	Brierley	Dec 1999	A
6007510	Nigam	Dec 1999	A
6007511	Prywes	Dec 1999	A
6030416	Huo et al.	Feb 2000	A
6033434	Borghi	Mar 2000	A
6036678	Giungo	Mar 2000	A
6036682	Lange et al.	Mar 2000	A
6045557	White et al.	Apr 2000	A
6050970	Baerveldt	Apr 2000	A
6050999	Paraschac et al.	Apr 2000	A
6059772	Hsia et al.	May 2000	A
6059812	Clerc et al.	May 2000	A
6060463	Freeman	May 2000	A
6063116	Kelleher	May 2000	A
6063396	Kelleher	May 2000	A
6071286	Mawad	Jun 2000	A
6077299	Adelberg et al.	Jun 2000	A
6102045	Nordquist et al.	Aug 2000	A
6110912	Kaufman et al.	Aug 2000	A
6123668	Abreu	Sep 2000	A
6135977	Drasler et al.	Oct 2000	A
6142990	Burk	Nov 2000	A
6146387	Trott et al.	Nov 2000	A
6159458	Bowman et al.	Dec 2000	A
6165210	Lau et al.	Dec 2000	A
6168575	Soltanpour	Jan 2001	B1
6174305	Mikus et al.	Jan 2001	B1
6177427	Clark et al.	Jan 2001	B1
6184250	Klimko et al.	Feb 2001	B1
6186974	Allan et al.	Feb 2001	B1
6187016	Hedges et al.	Feb 2001	B1
6193656	Jeffries et al.	Feb 2001	B1
6194415	Wheeler et al.	Feb 2001	B1
6197056	Schachar	Mar 2001	B1
6201001	Wang et al.	Mar 2001	B1
6203513	Yaron et al.	Mar 2001	B1
6217895	Guo et al.	Apr 2001	B1
6221078	Bylsma	Apr 2001	B1
6224570	Le et al.	May 2001	B1
6228873	Brandt et al.	May 2001	B1
6231597	Deem et al.	May 2001	B1
6231853	Hillman et al.	May 2001	B1
6241721	Cozean et al.	Jun 2001	B1
6251090	Avery et al.	Jun 2001	B1
6254612	Hieshima	Jul 2001	B1
6261256	Ahmed	Jul 2001	B1
6264668	Prywes	Jul 2001	B1
6266182	Morita	Jul 2001	B1
6268398	Ghosh et al.	Jul 2001	B1
6274138	Bandman et al.	Aug 2001	B1
6287256	Park et al.	Sep 2001	B1
6287313	Sasso	Sep 2001	B1
6299603	Hecker et al.	Oct 2001	B1
6299895	Hammang et al.	Oct 2001	B1
6306114	Freeman et al.	Oct 2001	B1
6331313	Wong et al.	Dec 2001	B1
6342058	Portney	Jan 2002	B1
6348042	Warren, Jr.	Feb 2002	B1
6355033	Moorman et al.	Mar 2002	B1
6358222	Grundei	Mar 2002	B1
6361519	Knudson et al.	Mar 2002	B1
6375642	Grieshaber et al.	Apr 2002	B1
6399734	Hodd et al.	Jun 2002	B1
6402734	Weiss	Jun 2002	B1
6405732	Edwards et al.	Jun 2002	B1
6413540	Yaacobi	Jul 2002	B1
6416777	Yaacobi	Jul 2002	B1
6428501	Reynard	Aug 2002	B1
6428566	Holt	Aug 2002	B1
6436427	Hammang et al.	Aug 2002	B1
6450937	Mercereau et al.	Sep 2002	B1
6450984	Lynch et al.	Sep 2002	B1
6454787	Maddalo et al.	Sep 2002	B1
6464724	Lynch et al.	Oct 2002	B1
6468283	Richter et al.	Oct 2002	B1
6494857	Neuhann	Dec 2002	B1
6508779	Suson	Jan 2003	B1
6510600	Yaron et al.	Jan 2003	B2
6517483	Park et al.	Feb 2003	B2
6524275	Lynch et al.	Feb 2003	B1
6530896	Elliott	Mar 2003	B1
6533768	Hill	Mar 2003	B1
6544249	Yu et al.	Apr 2003	B1
6548078	Guo et al.	Apr 2003	B2
6558342	Yaron et al.	May 2003	B1
6561974	Grieshaber et al.	May 2003	B1
6579235	Abita et al.	Jun 2003	B1
6579256	Hughes	Jun 2003	B2
6582426	Moorman et al.	Jun 2003	B2
6582453	Tran et al.	Jun 2003	B1
6585680	Bugge	Jul 2003	B2
6585753	Eder et al.	Jul 2003	B2
6589198	Soltanpour et al.	Jul 2003	B1
6589203	Mitrev	Jul 2003	B1
6595945	Brown	Jul 2003	B2
6605053	Kamm et al.	Aug 2003	B1
6607542	Wild	Aug 2003	B1
6613343	Dillingham et al.	Sep 2003	B2
6620154	Amirkhanian et al.	Sep 2003	B1
6622473	Lynch et al.	Sep 2003	B2
6626858	Lynch et al.	Sep 2003	B2
6629981	Bui et al.	Oct 2003	B2
6638239	Bergheim et al.	Oct 2003	B1
6666213	Svadovskiy	Dec 2003	B2
6666841	Gharib et al.	Dec 2003	B2
6676607	De Juan, Jr. et al.	Jan 2004	B2
6682500	Soltanpour et al.	Jan 2004	B2
6699211	Savage	Mar 2004	B2
6699272	Slepian et al.	Mar 2004	B2
6726676	Stegmann et al.	Apr 2004	B2
D490152	Myall et al.	May 2004	S
6730056	Ghaem et al.	May 2004	B1
6736791	Tu et al.	May 2004	B1
6763833	Khera et al.	Jul 2004	B1
6764439	Schaaf et al.	Jul 2004	B2
6767346	Damasco et al.	Jul 2004	B2
6780164	Bergheim et al.	Aug 2004	B2
6780165	Kadziauskas et al.	Aug 2004	B2
6783544	Lynch et al.	Aug 2004	B2
6827699	Lynch et al.	Dec 2004	B2
6827700	Lynch et al.	Dec 2004	B2
6827738	Willis et al.	Dec 2004	B2
6893413	Martin	May 2005	B2
6902577	Lipshitz et al.	Jun 2005	B2
6955656	Bergheim et al.	Oct 2005	B2
6962573	Wilcox	Nov 2005	B1
6966888	Cullen et al.	Nov 2005	B2
6981958	Gharib et al.	Jan 2006	B1
7033603	Nelson et al.	Apr 2006	B2
7041077	Shields	May 2006	B2
7077821	Durgin	Jul 2006	B2
7090681	Weber et al.	Aug 2006	B2
7094225	Tu et al.	Aug 2006	B2
7101402	Phelps et al.	Sep 2006	B2
7135009	Tu et al.	Nov 2006	B2
7135016	Asia et al.	Nov 2006	B1
7144616	Unger et al.	Dec 2006	B1
7163543	Smedley et al.	Jan 2007	B2
7186232	Smedley et al.	Mar 2007	B1
7192412	Zhou et al.	Mar 2007	B1
7192484	Chappa et al.	Mar 2007	B2
7217263	Humayun et al.	May 2007	B2
7220238	Lynch et al.	May 2007	B2
7273475	Tu et al.	Sep 2007	B2
7291125	Coroneo	Nov 2007	B2
7294115	Wilk	Nov 2007	B1
7297130	Bergheim et al.	Nov 2007	B2
7331984	Tu et al.	Feb 2008	B2
7344528	Tu et al.	Mar 2008	B1
7364564	Sniegowski et al.	Apr 2008	B2
7431710	Tu et al.	Oct 2008	B2
7488303	Haffner et al.	Feb 2009	B1
7520876	Ressemann et al.	Apr 2009	B2
RE40722	Chappa	Jun 2009	E
7563241	Tu et al.	Jul 2009	B2
7592016	Wong et al.	Sep 2009	B2
7641627	Camras et al.	Jan 2010	B2
7662123	Shields	Feb 2010	B2
7678065	Haffner et al.	Mar 2010	B2
7695135	Rosenthal	Apr 2010	B1
7708711	Tu et al.	May 2010	B2
7758624	Dorn et al.	Jul 2010	B2
7771388	Olsen et al.	Aug 2010	B2
7811268	Maldon Ado Bas	Oct 2010	B2
7815592	Coroneo	Oct 2010	B2
7850637	Lynch et al.	Dec 2010	B2
7850638	Coroneo	Dec 2010	B2
7857782	Tu et al.	Dec 2010	B2
7862531	Yaron et al.	Jan 2011	B2
7867186	Haffner et al.	Jan 2011	B2
7867205	Bergheim et al.	Jan 2011	B2
7879001	Haffner et al.	Feb 2011	B2
7879079	Tu et al.	Feb 2011	B2
7905904	Stone et al.	Mar 2011	B2
7931660	Aranyi et al.	Apr 2011	B2
7945336	Sauter-Starace et al.	May 2011	B2
7951155	Smedley et al.	May 2011	B2
7959632	Fugo	Jun 2011	B2
7967772	McKenzie et al.	Jun 2011	B2
7997460	Pardes et al.	Aug 2011	B2
8007459	Haffner et al.	Aug 2011	B2
8034016	Yaron et al.	Oct 2011	B2
8034105	Stegmann et al.	Oct 2011	B2
8062244	Tu et al.	Nov 2011	B2
8075511	Tu et al.	Dec 2011	B2
8118768	Tu et al.	Feb 2012	B2
8128588	Coroneo	Mar 2012	B2
8142364	Haffner et al.	Mar 2012	B2
8152752	Lynch et al.	Apr 2012	B2
8197418	Lal et al.	Jun 2012	B2
8267882	Euteneuer et al.	Sep 2012	B2
8267995	Castillejos	Sep 2012	B2
8273050	Bergheim et al.	Sep 2012	B2
8313454	Yaron et al.	Nov 2012	B2
8333742	Bergheim et al.	Dec 2012	B2
8337445	Tu et al.	Dec 2012	B2
8337509	Schieber et al.	Dec 2012	B2
8388568	Lynch et al.	Mar 2013	B2
8439972	Badawi et al.	May 2013	B2
8444588	Yablonski	May 2013	B2
8444589	Silvestrini	May 2013	B2
8506515	Burns et al.	Aug 2013	B2
8540659	Berlin	Sep 2013	B2
8579846	Tu et al.	Nov 2013	B2
8617094	Smedley et al.	Dec 2013	B2
8656958	Unger et al.	Feb 2014	B2
8657776	Wardle et al.	Feb 2014	B2
8679089	Berlin	Mar 2014	B2
8771217	Lynch et al.	Jul 2014	B2
8801648	Bergheim et al.	Aug 2014	B2
8808219	Bergheim et al.	Aug 2014	B2
8808220	Coroneo	Aug 2014	B2
8814820	Bergheim et al.	Aug 2014	B2
8852137	Horvath et al.	Oct 2014	B2
8852266	Brooks et al.	Oct 2014	B2
8882781	Smedley et al.	Nov 2014	B2
9155654	Tu et al.	Oct 2015	B2
9173775	Haffner et al.	Nov 2015	B2
9220632	Smedley et al.	Dec 2015	B2
20010025150	de Juan et al.	Sep 2001	A1
20020013546	Grieshaber et al.	Jan 2002	A1
20020013572	Berlin	Jan 2002	A1
20020026200	Savage	Feb 2002	A1
20020072673	Yamamoto et al.	Jun 2002	A1
20020082591	Haefliger	Jun 2002	A1
20020087111	Ethier et al.	Jul 2002	A1
20020099434	Buscemi et al.	Jul 2002	A1
20020111608	Baerveldt et al.	Aug 2002	A1
20020120284	Schachar et al.	Aug 2002	A1
20020120285	Schachar et al.	Aug 2002	A1
20020133168	Smedley et al.	Sep 2002	A1
20020143284	Tu et al.	Oct 2002	A1
20020156413	Williams et al.	Oct 2002	A1
20020165522	Holmen	Nov 2002	A1
20020177856	Richter et al.	Nov 2002	A1
20020188308	Tu et al.	Dec 2002	A1
20020193725	Odrich	Dec 2002	A1
20030014021	Holmen	Jan 2003	A1
20030014092	Neuhann	Jan 2003	A1
20030019833	Unger et al.	Jan 2003	A1
20030055372	Lynch et al.	Mar 2003	A1
20030060752	Bergheim et al.	Mar 2003	A1
20030069637	Lynch et al.	Apr 2003	A1
20030079329	Yaron et al.	May 2003	A1
20030088260	Smedley et al.	May 2003	A1
20030093084	Nissan et al.	May 2003	A1
20030097117	Buono	May 2003	A1
20030097151	Smedley et al.	May 2003	A1
20030105456	Lin	Jun 2003	A1
20030109907	Shadduck	Jun 2003	A1
20030135149	Cullen et al.	Jul 2003	A1
20030153863	Patel	Aug 2003	A1
20030181848	Bergheim et al.	Sep 2003	A1
20030187384	Bergheim et al.	Oct 2003	A1
20030187385	Bergheim et al.	Oct 2003	A1
20030195438	Petillo	Oct 2003	A1
20030208163	Yaron et al.	Nov 2003	A1
20030208217	Dan	Nov 2003	A1
20030212383	Cote et al.	Nov 2003	A1
20030229303	Haffner et al.	Dec 2003	A1
20030236483	Ren	Dec 2003	A1
20030236484	Lynch et al.	Dec 2003	A1
20040024345	Gharib et al.	Feb 2004	A1
20040050392	Tu et al.	Mar 2004	A1
20040059248	Messner et al.	Mar 2004	A1
20040076676	Tojo et al.	Apr 2004	A1
20040088048	Richter et al.	May 2004	A1
20040092856	Dahan	May 2004	A1
20040098122	Lee et al.	May 2004	A1
20040102729	Haffner et al.	May 2004	A1
20040111050	Smedley et al.	Jun 2004	A1
20040127843	Tu et al.	Jul 2004	A1
20040147870	Burns et al.	Jul 2004	A1
20040154946	Solovay et al.	Aug 2004	A1
20040162545	Brown et al.	Aug 2004	A1
20040193095	Shadduck	Sep 2004	A1
20040193262	Shadduck	Sep 2004	A1
20040210181	Vass et al.	Oct 2004	A1
20040210185	Tu et al.	Oct 2004	A1
20040215126	Ahmed	Oct 2004	A1
20040225250	Yablonski	Nov 2004	A1
20040236343	Taylor et al.	Nov 2004	A1
20040243227	Starksen et al.	Dec 2004	A1
20040249404	Haefliger	Dec 2004	A1
20040254517	Quiroz-Mercado et al.	Dec 2004	A1
20040254520	Porteous et al.	Dec 2004	A1
20040254521	Simon	Dec 2004	A1
20040260227	Lisk, Jr. et al.	Dec 2004	A1
20050038334	Lynch et al.	Feb 2005	A1
20050038498	Dubrow et al.	Feb 2005	A1
20050049578	Tu et al.	Mar 2005	A1
20050055075	Pinchuk et al.	Mar 2005	A1
20050096639	Slatkine et al.	May 2005	A1
20050107734	Coroneo	May 2005	A1
20050119601	Lynch et al.	Jun 2005	A9
20050119737	Bene et al.	Jun 2005	A1
20050125003	Pinchuk et al.	Jun 2005	A1
20050165385	Simon	Jul 2005	A1
20050171562	Criscuolo et al.	Aug 2005	A1
20050182350	Nigam	Aug 2005	A1
20050184004	Rodgers et al.	Aug 2005	A1
20050192527	Gharib et al.	Sep 2005	A1
20050209672	George et al.	Sep 2005	A1
20050240143	Dohlman	Oct 2005	A1
20050250788	Tu et al.	Nov 2005	A1
20050261624	Wilcox	Nov 2005	A1
20050267397	Bhalla	Dec 2005	A1
20050267398	Protopsaltis et al.	Dec 2005	A1
20050267478	Corradi et al.	Dec 2005	A1
20050271704	Tu et al.	Dec 2005	A1
20050273033	Grahn et al.	Dec 2005	A1
20050277864	Haffner et al.	Dec 2005	A1
20050283108	Savage	Dec 2005	A1
20060032507	Tu	Feb 2006	A1
20060036207	Koonmen et al.	Feb 2006	A1
20060069340	Simon	Mar 2006	A1
20060079828	Brown	Apr 2006	A1
20060106370	Baerveldt et al.	May 2006	A1
20060116626	Smedley et al.	Jun 2006	A1
20060129129	Smith	Jun 2006	A1
20060155238	Shields	Jul 2006	A1
20060155300	Stamper et al.	Jul 2006	A1
20060173397	Tu et al.	Aug 2006	A1
20060200113	Haffner et al.	Sep 2006	A1
20060210605	Chang et al.	Sep 2006	A1
20060217741	Ghannoum	Sep 2006	A1
20060235367	Takashima et al.	Oct 2006	A1
20060241580	Mittelstein et al.	Oct 2006	A1
20060276739	Brown	Dec 2006	A1
20070004998	Rodgers et al.	Jan 2007	A1
20070021653	Hattenbach et al.	Jan 2007	A1
20070073275	Conston et al.	Mar 2007	A1
20070073390	Lee	Mar 2007	A1
20070078371	Brown et al.	Apr 2007	A1
20070078471	Schachar et al.	Apr 2007	A1
20070088242	Coroneo	Apr 2007	A1
20070093740	Shetty	Apr 2007	A1
20070106199	Krivoy et al.	May 2007	A1
20070106200	Levy	May 2007	A1
20070106235	Coroneo	May 2007	A1
20070112292	Tu et al.	May 2007	A1
20070118065	Pinchuk et al.	May 2007	A1
20070118066	Pinchuk et al.	May 2007	A1
20070123812	Pinchuk et al.	May 2007	A1
20070123919	Schachar et al.	May 2007	A1
20070149915	Yablonski	Jun 2007	A1
20070149927	Itou et al.	Jun 2007	A1
20070154621	Raad	Jul 2007	A1
20070156079	Brown	Jul 2007	A1
20070161981	Sanders et al.	Jul 2007	A1
20070179426	Selden	Aug 2007	A1
20070179471	Christian et al.	Aug 2007	A1
20070185468	Prywes	Aug 2007	A1
20070191863	De Juan et al.	Aug 2007	A1
20070202186	Yamamoto et al.	Aug 2007	A1
20070207186	Scanlon et al.	Sep 2007	A1
20070212386	Patravale et al.	Sep 2007	A1
20070212387	Patravale et al.	Sep 2007	A1
20070212388	Patravale et al.	Sep 2007	A1
20070212393	Patravale et al.	Sep 2007	A1
20070219632	Castillejos	Sep 2007	A1
20070233037	Gifford, III et al.	Oct 2007	A1
20070260201	Prausnitz et al.	Nov 2007	A1
20070276315	Haffner	Nov 2007	A1
20070276316	Haffner	Nov 2007	A1
20070282245	Tu et al.	Dec 2007	A1
20070287958	McKenzie et al.	Dec 2007	A1
20070292470	Thornton	Dec 2007	A1
20070292474	Hsu et al.	Dec 2007	A1
20070293807	Lynch et al.	Dec 2007	A1
20070293872	Peyman	Dec 2007	A1
20070293873	Chang	Dec 2007	A1
20070298068	Badawi et al.	Dec 2007	A1
20080027304	Pardo et al.	Jan 2008	A1
20080033351	Trogden et al.	Feb 2008	A1
20080039931	Jelle et al.	Feb 2008	A1
20080051681	Schwartz	Feb 2008	A1
20080058704	Hee et al.	Mar 2008	A1
20080082078	Berlin	Apr 2008	A1
20080091224	Griffis, III et al.	Apr 2008	A1
20080097214	Meyers et al.	Apr 2008	A1
20080097335	Trogden et al.	Apr 2008	A1
20080108932	Rodgers	May 2008	A1
20080108933	Yu et al.	May 2008	A1
20080108934	Berlin	May 2008	A1
20080109037	Steiner et al.	May 2008	A1
20080114440	Hlavka et al.	May 2008	A1
20080125691	Yaron et al.	May 2008	A1
20080140059	Schachar et al.	Jun 2008	A1
20080147083	Vold et al.	Jun 2008	A1
20080161741	Bene et al.	Jul 2008	A1
20080161907	Chen et al.	Jul 2008	A1
20080183289	Werblin	Jul 2008	A1
20080188860	Vold	Aug 2008	A1
20080195027	Coroneo	Aug 2008	A1
20080200860	Tu et al.	Aug 2008	A1
20080200923	Beckman et al.	Aug 2008	A1
20080208176	Loh	Aug 2008	A1
20080210322	Unger et al.	Sep 2008	A1
20080215062	Bowen et al.	Sep 2008	A1
20080221501	Cote et al.	Sep 2008	A1
20080228127	Burns et al.	Sep 2008	A1
20080236669	Unger et al.	Oct 2008	A1
20080243156	John	Oct 2008	A1
20080243243	Williams et al.	Oct 2008	A1
20080243247	Poley et al.	Oct 2008	A1
20080255545	Mansfield et al.	Oct 2008	A1
20080269730	Dotson	Oct 2008	A1
20080277007	Unger et al.	Nov 2008	A1
20080281250	Bergsneider et al.	Nov 2008	A1
20080289710	Unger et al.	Nov 2008	A1
20080306429	Shields et al.	Dec 2008	A1
20090036818	Grahn et al.	Feb 2009	A1
20090043242	Bene et al.	Feb 2009	A1
20090043321	Conston et al.	Feb 2009	A1
20090043365	Friedland et al.	Feb 2009	A1
20090076436	Gharib et al.	Mar 2009	A2
20090082860	Schieber et al.	Mar 2009	A1
20090082862	Schieber et al.	Mar 2009	A1
20090082863	Schieber et al.	Mar 2009	A1
20090112245	Haefliger	Apr 2009	A1
20090124973	D'Agostino et al.	May 2009	A1
20090132040	Frion et al.	May 2009	A1
20090137989	Kataoka	May 2009	A1
20090137992	Mallakrishnan	May 2009	A1
20090151422	Unger et al.	Jun 2009	A1
20090177138	Brown et al.	Jul 2009	A1
20090177245	Ameri et al.	Jul 2009	A1
20090182421	Silvestrini et al.	Jul 2009	A1
20090198213	Tanaka	Aug 2009	A1
20090204053	Nissan et al.	Aug 2009	A1
20090227934	Euteneuer et al.	Sep 2009	A1
20090264813	Chang	Oct 2009	A1
20090275924	Lattanzio et al.	Nov 2009	A1
20090287136	Castillejos	Nov 2009	A1
20090287233	Huculak	Nov 2009	A1
20090326432	Schmidt et al.	Dec 2009	A1
20100004581	Brigatti et al.	Jan 2010	A1
20100004635	Lin et al.	Jan 2010	A1
20100010416	Juan, Jr. et al.	Jan 2010	A1
20100010452	Paques	Jan 2010	A1
20100025613	Tai et al.	Feb 2010	A1
20100030150	Paques et al.	Feb 2010	A1
20100042209	Guarnieri	Feb 2010	A1
20100056977	Wandel	Mar 2010	A1
20100056979	Smedley et al.	Mar 2010	A1
20100057055	Camras et al.	Mar 2010	A1
20100057093	Ide et al.	Mar 2010	A1
20100076419	Chew et al.	Mar 2010	A1
20100106073	Haffner et al.	Apr 2010	A1
20100114006	Baerveldt	May 2010	A1
20100121248	Yu et al.	May 2010	A1
20100121249	Yu et al.	May 2010	A1
20100121342	Schieber et al.	May 2010	A1
20100125237	Schocket	May 2010	A1
20100137981	Silvestrini et al.	Jun 2010	A1
20100152626	Schwartz	Jun 2010	A1
20100152641	Yablonski	Jun 2010	A1
20100168644	Brown	Jul 2010	A1
20100173866	Hee et al.	Jul 2010	A1
20100175767	Unger et al.	Jul 2010	A1
20100185138	Yaron et al.	Jul 2010	A1
20100185205	Novakovic et al.	Jul 2010	A1
20100191103	Stamper et al.	Jul 2010	A1
20100191329	Badawi et al.	Jul 2010	A1
20100222733	Schieber et al.	Sep 2010	A1
20100234791	Lynch et al.	Sep 2010	A1
20100240987	Christian et al.	Sep 2010	A1
20100241046	Pinchuk et al.	Sep 2010	A1
20100249691	Van Der Mooren et al.	Sep 2010	A1
20100262174	Sretavan	Oct 2010	A1
20100274258	Silvestrini et al.	Oct 2010	A1
20100274259	Yaron et al.	Oct 2010	A1
20100280317	Silvestrini et al.	Nov 2010	A1
20110009874	Wardle et al.	Jan 2011	A1
20110009958	Wardle et al.	Jan 2011	A1
20110022065	Shipp	Jan 2011	A1
20110028883	Juan, Jr. et al.	Feb 2011	A1
20110028884	Coroneo	Feb 2011	A1
20110028983	Silvestrini et al.	Feb 2011	A1
20110046536	Stegmann et al.	Feb 2011	A1
20110046728	Shareef et al.	Feb 2011	A1
20110066098	Stergiopulos	Mar 2011	A1
20110071454	Dos Santos et al.	Mar 2011	A1
20110071456	Rickard	Mar 2011	A1
20110071458	Rickard	Mar 2011	A1
20110071459	Rickard et al.	Mar 2011	A1
20110071505	Rickard et al.	Mar 2011	A1
20110071524	Keller	Mar 2011	A1
20110077626	Baerveldt et al.	Mar 2011	A1
20110082385	Diaz et al.	Apr 2011	A1
20110087151	Coroneo	Apr 2011	A1
20110092878	Tu et al.	Apr 2011	A1
20110092965	Slatkine et al.	Apr 2011	A1
20110098627	Wilcox	Apr 2011	A1
20110098629	Juan, Jr. et al.	Apr 2011	A1
20110098809	Wardle et al.	Apr 2011	A1
20110105987	Bergheim et al.	May 2011	A1
20110112546	Juan, Jr. et al.	May 2011	A1
20110118649	Stegmann et al.	May 2011	A1
20110118835	Silvestrini et al.	May 2011	A1
20110130831	Badawi et al.	Jun 2011	A1
20110144559	Lafdi et al.	Jun 2011	A1
20110144641	Dimalanta, Jr. et al.	Jun 2011	A1
20110196487	Badawi et al.	Aug 2011	A1
20110202049	Jia et al.	Aug 2011	A1
20110224597	Stegmann et al.	Sep 2011	A1
20110230877	Huculak et al.	Sep 2011	A1
20110306915	De Juan, Jr. et al.	Dec 2011	A1
20110319793	Hynynen	Dec 2011	A1
20110319806	Wardle	Dec 2011	A1
20120010702	Stegmann et al.	Jan 2012	A1
20120016286	Silvestrini et al.	Jan 2012	A1
20120022409	Gertner et al.	Jan 2012	A1
20120022424	Yamamoto et al.	Jan 2012	A1
20120022429	Silvestrini et al.	Jan 2012	A1
20120035524	Silvestrini	Feb 2012	A1
20120035525	Silvestrini	Feb 2012	A1
20120059461	Badawi et al.	Mar 2012	A1
20120065570	Yeung et al.	Mar 2012	A1
20120071908	Sorensen et al.	Mar 2012	A1
20120078158	Haffner et al.	Mar 2012	A1
20120078281	Cox et al.	Mar 2012	A1
20120089072	Cunningham, Jr.	Apr 2012	A1
20120089073	Cunningham, Jr.	Apr 2012	A1
20120123439	Romoda et al.	May 2012	A1
20120123440	Horvath et al.	May 2012	A1
20120130467	Selden et al.	May 2012	A1
20120165721	Grabner et al.	Jun 2012	A1
20120165722	Horvath et al.	Jun 2012	A1
20120165723	Horvath et al.	Jun 2012	A1
20120179087	Schieber et al.	Jul 2012	A1
20120184892	Bigler et al.	Jul 2012	A1
20120197175	Horvath et al.	Aug 2012	A1
20120203160	Kahook et al.	Aug 2012	A1
20120203262	Connors et al.	Aug 2012	A1
20120220917	Silvestrini et al.	Aug 2012	A1
20120232570	Jenson et al.	Sep 2012	A1
20120271272	Hammack et al.	Oct 2012	A1
20120283557	Berlin	Nov 2012	A1
20120289883	Meng et al.	Nov 2012	A1
20120302861	Marshall et al.	Nov 2012	A1
20120310072	Grieshaber	Dec 2012	A1
20120310137	Silvestrini	Dec 2012	A1
20120323159	Wardle et al.	Dec 2012	A1
20130006164	Yaron et al.	Jan 2013	A1
20130006165	Euteneuer et al.	Jan 2013	A1
20130018295	Haffner et al.	Jan 2013	A1
20130018412	Journey et al.	Jan 2013	A1
20130079701	Schieber et al.	Mar 2013	A1
20130079759	Dotson et al.	Mar 2013	A1
20130090534	Burns et al.	Apr 2013	A1
20130102949	Baerveldt	Apr 2013	A1
20130110125	Silvestrini et al.	May 2013	A1
20130131577	Bronstein et al.	May 2013	A1
20130144202	Field et al.	Jun 2013	A1
20130150770	Horvath et al.	Jun 2013	A1
20130150773	Nissan et al.	Jun 2013	A1
20130150774	Field et al.	Jun 2013	A1
20130150776	Bohm et al.	Jun 2013	A1
20130150777	Bohm et al.	Jun 2013	A1
20130150779	Field	Jun 2013	A1
20130150959	Schieber et al.	Jun 2013	A1
20130158381	Rickard	Jun 2013	A1
20130158462	Wardle et al.	Jun 2013	A1
20130165840	Orge	Jun 2013	A1
20130172804	Schieber et al.	Jul 2013	A1
20130184631	Pinchuk	Jul 2013	A1
20130245532	Tu et al.	Sep 2013	A1
20130253404	Tu et al.	Sep 2013	A1
20130253405	Tu	Sep 2013	A1
20130253528	Haffner et al.	Sep 2013	A1
20130281910	Tu et al.	Oct 2013	A1
20140034607	Meng et al.	Feb 2014	A1
20140046437	Renke	Feb 2014	A1
20140052046	Peartree et al.	Feb 2014	A1
20140081194	Burns et al.	Mar 2014	A1
20140135916	Clauson et al.	May 2014	A1
20140155803	Silvestrini	Jun 2014	A1
20140276332	Crimaldi et al.	Sep 2014	A1
20140343475	Smedley et al.	Nov 2014	A1
20150065940	Rangel-Friedman et al.	Mar 2015	A1
20150148730	Lynch et al.	May 2015	A1
20150223981	Smedley et al.	Aug 2015	A1
20150374546	Hill	Dec 2015	A1
20160151204	Haffner et al.	Jun 2016	A1

Foreign Referenced Citations (80)

Number	Date	Country
200072059	Jul 2001	AU
2004264913	Feb 2005	AU
2009251058	Dec 2013	AU
2273331	Jun 1998	CA
2244646	Feb 1999	CA
2311244	Jun 1999	CA
2643357	Nov 1999	CA
2683224	Dec 2014	CA
19840047	Mar 2000	DE
0436232	Jul 1991	EP
0550791	Jul 1993	EP
0858788	Aug 1998	EP
0881055	Dec 1998	EP
0898947	Mar 1999	EP
1114627	Jul 2001	EP
1977724	Oct 2008	EP
2088976	Aug 2009	EP
2260803	Dec 2010	EP
2351589	Aug 2011	EP
2710269	Mar 1995	FR
2721499	Dec 1995	FR
2757068	Jun 1998	FR
2296663	Jul 1996	GB
11-123205	May 1999	JP
3703721	Jul 2005	JP
4688444	Feb 2011	JP
5255402	Apr 2013	JP
5323011	Jul 2013	JP
2143250	Dec 1999	RU
WO 8900869	Feb 1989	WO
WO 9108784	Jun 1991	WO
WO 9118568	Dec 1991	WO
WO 9200112	Jan 1992	WO
WO 9208406	May 1992	WO
WO 9219294	Nov 1992	WO
WO 9402081	Feb 1994	WO
WO9413234	Jun 1994	WO
WO 9421205	Sep 1994	WO
WO 9508310	Mar 1995	WO
WO 9508310	Mar 1995	WO
WO 9620742	Jul 1996	WO
WO 9636377	Nov 1996	WO
WO 9823237	Jun 1998	WO
WO 9830181	Jul 1998	WO
WO 9830181	Jul 1998	WO
WO 9835639	Aug 1998	WO
WO 9837831	Sep 1998	WO
WO 9926567	Jun 1999	WO
WO 9930641	Jun 1999	WO
WO 9930644	Jun 1999	WO
WO 9938470	Aug 1999	WO
WO 9938470	Aug 1999	WO
WO 0013627	Mar 2000	WO
WO 0064389	Nov 2000	WO
WO 0064390	Nov 2000	WO
WO 0064391	Nov 2000	WO
WO 0064393	Nov 2000	WO
WO 0072788	Dec 2000	WO
WO 0150943	Jul 2001	WO
WO 0178631	Oct 2001	WO
WO 0178656	Oct 2001	WO
WO 0185065	Nov 2001	WO
WO 0197727	Dec 2001	WO
WO 0236052	May 2002	WO
WO 02074052	Sep 2002	WO
WO 02080811	Oct 2002	WO
WO 02102274	Dec 2002	WO
WO 03015659	Feb 2003	WO
WO 03041622	May 2003	WO
WO 03045290	Jun 2003	WO
WO 03073968	Sep 2003	WO
WO 2005055873	Jun 2005	WO
WO 2005107845	Nov 2005	WO
WO 2008061043	May 2008	WO
WO 2009012406	Jan 2009	WO
WO 2010093945	Aug 2010	WO
WO 2011020633	Feb 2011	WO
WO 2012071476	May 2012	WO
WO 2013148275	Oct 2013	WO
WO 2014151070	Sep 2014	WO

Non-Patent Literature Citations (232)

Entry
Portney, GL. “Silicone Elastomer Implantation Cyclodialysis,” Arch Ophthalmol. 89, 10-12 (1973).
Bahler, Cindy K., BS, Gregrory T. Smedley, PhD, Jianbo Zhou, PhD, Douglas H. Johnson, MD., Trabecular Bypass Stents Decrease Intraocular Pressure in Cultured Human Anterior Segments, American Journal of Ophthalmology, Dec. 2004, vol. 138, pp. 988-994.
Bietti, G.B., “The Present State of the Use of Plastics in Eye Surgery,” Acta Ophthalmologica, vol. 33, No. 4 (1955).
Coote, M. A., “Glaucoma Hollow Fiber Filters—A New Glaucoma Seton. Preliminary Results,” J. Glaucoma, vol. 8, No. 1, Supplement (1999).
Cullen et al., “Anterior Chamber to Frontal Sinus Shunt for the Diversion of Aqueous Humor: A Pilot Study in Four Normal Dogs,” Veterinary Ophthalmology, vol. 1, No. 1 (1998).
Dorland's Illustrated Medical Dictionary, 28th Edition, Philadelphia: W.B. Saunders Company, 1994, p. 167.
Emi, Kazayuki, et al., Hydrostatic Pressure of the Suprachoroidal Space, Investigative Ophthalmology & Visual Science, vol. 30, No. 2, Feb. 1989 (pp. 233-238).
Extended European Search Report in European Application No. 08102896.1, dated Sep. 5, 2008, 7 pages.
Fletcher, Daniel A., Ph.D., Daniel V. Palanker, Ph.D., Philip Hule, M.D., Jason Miller, MS, Michael F. Marmor, M.D. and Mark S. Blumenkranz, M.D.; Intravascular Drug Delivery With a Pulsed Liquid Microjet; (Reprinted) Arch Ophthalmology; vol. 120, Sep. 2002, pp. 1206-1208.
Grant, W.M., MD, Further Studies on Facility of Flow Through the Trabecular Meshwork, AMA Archives of Ophthalmology, Oct. 1958, vol. 60, pp. 523-533.
Green, K. et. al, “Fate of Anterior Chamber Tracers in the Living Rhesus Monkey Eye with Evidence for Uveo-Vortex Outflow,” Fourth William Mackenzie Memorial Symposium, 1977, pp. 731-739.
Grierson, I., R.C. Howes, and Q. Wang, Age-related Changes in the Canal of Schlemm, Exp. Eye Res., 1984, vol. 39, pp. 505-512.
Hill, R.A., Q. Ren, D.C. Nguyen, L.H. Liaw, & M.W. Berns, Free-electron Laser (FEL) Ablation of Ocular Tissues, Lasers Med Sci 1998, vol. 13, pp. 219-226.
Hill, Richard A., MD, George Baerveldt, MD, Serdar A. Ozler, MD, Michael Pickford, BA, Glen A. Profeta, BS, & Michael W. Berns, PhD, Laser Trabecular Ablation (LTA), Lasers in Surgery and Medicine, 1991, vol. 11, pp. 341-346.
Hoerauf, Hans, Christopher Wirbelauer, Christian Scholz, Ralf Engelhardt, Peter Koch, Horst Laqua, and Reginald Birngruber, Slit-lamp-adapted optical coherence tomography of the anterior segment, Graefe's Arch Clin Exp Ophthalmol, 2000, vol. 238, pp. 8-18.
Jacobi, Phillip C., MD, Thomas S. Dietlein, MD and Gunter K. Krieglstein, MD, Microendoscopic Trabecular Surgery in Glaucoma Management, Ophthalmology, 1999 vol. 106, No. 3, pp. 538-544
Jacobi, Phillip C., MD, Thomas S. Dietlein, MD and Gunter K. Krieglstein, MD, Bimanual Trabecular Aspiration in Pseudoexfoliation Glaucoma, Ophthalmology, 1998, vol. 105, No. 5, May 1998, pp. 886-894
Jacobi, Phillip C., MD, Thomas S. Dietlein, MD and Gunter K. Krieglstein, MD, Goniocurettage for Removing Trabecular Meshwork: Clinical Results of a new Surgical American Journal of Technique in Advanced Chronic Open-Angle Glaucoma, Ophthalmology, May 1999, pp. 505-510
Jocson, Vincente, L., M.D.; Air Trabeculotomy, American Journal of Ophthalmolgy: vol. 79, o. 1, Jan.-Jun. 1975; pp. 107-111.
Johnstone, M.A., R. Stegmann, and B.A. Smit, American Glaucoma Society, 12th Annual Meeting, Cylindrical Tubular Structures Spanning from Trabecular Meshwork Across SC, Laboratory Studies with SEM, TEM and Tracers Correlated with Clinical Findings, Abstract No. 18., p. 39, 2002.
Jordon, et al., “A Novel Approach to Suprachoroidal Drainage for the Surgical Treatment of Intractable Glaucoma,” J Glaucoma 15(3): 200-205 (2006).
Jordan, Jens, Thomas S. Dietlein, Sven Dinslage, Christoph Lüke, Walter Konen, Günter K. Krieglstein, Cyclodialysis ab interno as a surgical approach to intractable glaucoma, Graefe's Arch Clin Exp Ophthalmol (2007) 245:1071-1076.
Kampik, Anselm Franz Grehn, Nutzen and Risiken Augenärzticher Therapie, Hauptreferate der XXXII, Essener Fortbilding für Augenärtze, Dec. 1998. (English translated version enclosed Benefiets and Risks of Ophthalmological Therapy).
Katz, L. Jay, MD, A Call for Innovative Operations for Glaucoma, Arch Ophthalmology, Mar. 2000, vol. 118, pp. 412-413.
Klemm, A. Balazs, J. Draeger, R. Wiezorrek, Experimental use of space-retaining substances with extended duration: functional and morphological results, Graefe's Arch Clin Exp Ophthalmol (1995) 233:592-597.
Krejci, L., “Cyclodialysis with Hydroxyethyl Methacrylate Capillary Strip (HCS),” Opthalmologica, vol. 164 (1972).
Lee, P.F. et al., “Aqueous-venous Shunt and Intraocular Pressure. Preliminary Report of Animal Studies.” (1966).
Llobet, et al., Understanding Trabecular Meshwork Physiology: A Key to the Control of Intraocular Pressure?, News Physiol Sci vol. 18, pp. 205-209 (2003).
Luntz, Maurice H., MD & D.G. Livingston, B.SC., Trabeculotomy AB Externo & Trabeculectomy in Congenital and Adult-Onset Glaucoma, American Journal of Ophthalmology, Feb. 1977, vol. 83, No. 2, pp. 174-179.
Matsumoto, Yasuhiro and Douglas H. Johnson, Trabecular Meshwork Phagocytosis in Graucomatous Eyes, Ophthalmologica 1977, vol. 211, pp. 147-152.
McGehee, Blake E. et al., “Bilateral Retinal Detachment in a Patient with Vogt-Koyanagi-Harada Syndrome,” Emergency Radiology (2005) 11: 366-371.
Nickells, Robert W., Apoptosis of Retinal Ganglion Cells in Glaucoma: An Update of the Molecular Pathways Involved in Cell Death, Survey of Ophthalmology, vol. 43, Supplement 1, Jun. 1999, pp. S-151 through S-161.
Odrich, S., “New Technique During Complex Tube-Shunt Implantation,” Journal of Glaucoma, vol. 9 (2000).
Olsen, et al., “Cannulation of the Suprachoroidal Space: A Novel Drug Delivary Methodology to the Posterior Segment”, American Journal of Ophthalmology, Nov. 2006, pp. 777-787.e2 (13 pages).
Pederson, Jonathan et al., “Uveoscleral Aqueous Outflow in the Rhesus Monkey: Importance of Uveal Reabsorption,” Invest. Ophthalmol, Visual Sci. Nov. 1977, Uveal Reabsorption of Aqueous Humor, vol. 16, No. 11, pp. 1008-1017.
Putney, Luanna K., Cecile Rose T. Vibat, and Martha E. O'Donnell, Intracellular C1 Regulates Na-K-C1 Cotransport Activity in Human Trabecular Meshwork Cells, 1999 American Physiological Society, Sep. 1999, pp. C373 through C383.
Radhakrishnan, Sumita, Andrew M. Rollins, Jonathan E. Roth, S. Yazddanfar, Volker Westphal, David Bardenstein, and Joseph Izatt, Real-Time Optical Coherence Tomography of the Anterior Segment at 1310 nm, Arch Ophthalmology, Aug. 2001, vol. 119, pp. 1179-1185.
Rohen, Johannes W., Grune & Stratton, Harcourt Brace Jovanovich Publishers, edited by J.E. Cairns, Glaucoma, vol. 1, Chapter 14, Anatomy of the Aqueous Outflow Channels, 1986 pp. 277-296.
Rosenberg, et al., “Implants in Glaucoma Surgery”, The Glaucomas 1996, Chapter 88, pp. 1783-1807 (27 pages).
Rowan, MD, Combined Cyclodialysis and Cataract Surgery, Ophthalmic Surgery and Lasers, Dec. 1998, vol. 29, No. 12, pp. 962-968 (9 pages).
Schwartz, Arthur L., MD, & Douglas R. Anderson, MD, Trabecular Surgery, Arch Ophthalmol, vol. 92, Aug. 1974, pp. 134-138.
Shields, M. Bruce, MD, A Study Guide for Glaucoma: Aqueous Humor Dynamics, Copyright 1982, pp. 6-43.
Shields, M. Bruce, Aqueous Humor Dynamics, Textbook of Glaucoma, Fourth Ed., Williams & Wilkins Publishers, 1998, Ch. 2, pp. 5-31.
Spiegel, Detliev, MD, Karin Kobuch, MD, Richard A. Hill, MD, Ronald L. Gross, MD, Schlemm's Canal Implant: A New Method to Lower Intraocular Pressure in Patients With POAG?, Opthalmic Surgery and Lasers, Jun. 1999, vol. 30, No. 6, pp. 492-494.
Strange, Kevin (edited by), Cellular and Molecular Physiology of Cell Volume Regulation, Library of Congress Cataloging in-Publication Data, CRC Press, Inc., 1994 pp. 312-321.
Tatton, W.G., Apoptotic Mechanisms in Neurodegeneration: Possible Relevance to Glaucoma, European Journal of Ophthalmology, Jan.-Mar. 1999, vol. 9, Supplement 1, pp. S22 through S29.
Tatton, William, Ruth M.E. Chalmers-Redman, Ajay Sud, Steven M. Podos, and Thomas Mittag, Maintaining Mitochondrial Membrane Impermeability: An Opportunity for New Therapy in Glaucoma, Survey of Ophthalmology, vol. 45, Supplement 3, May 2001, pp. S277 through S283.
Troncoso, M.U. “Cyclodialysis with Insertion of a Metal Implant in the Treatment of Glaucoma,” Archives of Ophthalmology, vol. 23 (1940).
Troncoso, M.U. “Use of the Tantalum Implants for Inducing a Permanent Hypotony in Rabbits' Eyes,” American Journal of Ophthalmology, vol. 32, No. 4 (1949).
U.S. Appl. No. 09/452,963, filed Dec. 2, 1999. Title: Expandable/Retractable Stent for Venous and Valvular Annulus Use.
Wagner, Justin A., Edwards, Aurélie, and Schuman, Joel S., Characterization of Uveoscleral Outflow in Enucleated Porcine Eyes Perfused Under Constant Pressure, Invest Ophthalmol Vis Sci. Sep. 2004; 45(9): 3203-3206 (9 pages).
Zhou, Jianbo, PhD, Gregory T. Smedley, PhD., A Trabecular Bypass Flow Hypothesis, Feb. 2005, vol. 14 No. 1, pp. 74-83.
Toris, Carol B. “Aqueous humor dynamics I.” Current topics in membranes. In: Civan, MM (Ed.) The Eye's Aqueous Humor, 62 (2008): 193-229).
The Glaucomas, 2nd Edition, Ritch, Robert, MD, et al, Chapter 15 “Uveoscleral Outflow” 1996.
Transcend Medical, Inc.'s Disclosures Pursuant to Default Discovery Rule 4(d) (Dec. 6, 2013) (341 pages).
Transcend Medical, Inc.'s Preliminary Invalidity Contentions for U.S. Pat. No. 8,579,846 (Mar. 3, 2014) (184 pages).
Transcend Medical, Inc.'s First Supplemental Invalidity Contentions (Mar. 3, 2014) (107 pages).
Glaukos Corporation's First Supplemental Response to Transcend Medical, Inc.'s Interrogatories Nos. 1-2, 4, 6 and 9 (Mar. 13, 2014) (12 pages).
Complaint for Declaratory Judgment of Patent Non-Infringement and Invalidity (May 10, 2013).
Answer and Counterclaim (May 31, 2013).
Plaintiff Transcend Medical Inc.'s Answer to Counterclaims (Jun. 24, 2013).
Glaukos Corporation's Responses to Transcend Medica, Inc.'s First Set of Interrogations (Nos. 1-11) (Aug. 15, 2013).
Glaukos Corporation's Responses To Transcend Medical, Inc.'s Second Set Of Interrogatories (No. 12) dated Jun. 26, 2014.
Glaukos Corporation's Responses To Transcend Medical, Inc.'s Third Set Of Interrogatories (No. 13) dated Jul. 7, 2014.
Glaukos Corporation's Responses To Transcend Medical, Inc.'s Fourth Set Of Interrogatories (Nos. 14-15) dated Aug. 29, 2014.
Glaukos Corporation's Supplemental Response To Transcend Medical, Inc.'s Interrogatory No. 3 dated Aug. 29, 2014.
Glaukos Corporation's Responses To Transcend Medical, Inc.'s Sixth Set Of Interrogatories (Nos. 20-25) dated Nov. 21, 2014.
Glaukos Corporation's Supplemental Response To Transcend Medical, Inc.'s Third Set Of Interrogatories (No. 13) dated Nov. 21, 2014.
Transcend Medical, Inc.'s First Supplemental Response To Glaukos Corporation's Interrogatory No. 1 dated Dec. 23, 2013.
Redacted Exhibits A-C of Transcend Medical, Inc.'s First Supplemental Response To Glaukos Corporation's Interrogatory No. 1 dated Dec. 23, 2013.
Transcend Medical, Inc.'s Responses and Objections To Glaukos Corporation's First Set of Interrogatories dated Oct. 24, 2013.
Transcend Medical, Inc.'s Second Supplemental Response To Glaukos Corporation's Interrogatory No. 1 dated Mar. 3, 2014.
Transcend Medical, Inc.'s Responses and Objections To Glaukos Corporation's Second Set of Interrogatories dated May 27, 2014.
Glaukos Corporation's Objections and Responses To Transcend Medical, Inc.'s First Set of Requests for Admission dated Aug. 29, 2014.
Amendment Accompanying Request for Continued Examination and Response to Office Action dated Mar. 16, 2010, filed in U.S. Appl. No. 10/987,114 (Jun. 15, 2010)(12 pages)
Notice of Allowability in U.S. Appl. No. 10/987,114 (Jul. 29, 2010)(3 pages).
Communication from European Patent Office for European App. No. 08102896.1 (Jul. 2, 2012) (5 pages).
Hoskins, H. Dunbar, et al., Diagnosis and Therapy of the Glaucomas, Chapter 4: Aqueous Humor Outflow, 6th edition, pp. 41-66 (1989) (28 pages).
Sherman, Steven H., et al., “The Fate of Anterior Chamber Fluorescein in the Monkey Eye 1. The Anterior Chamber Outflow Pathways”, Exp. Eye Res. vol. 27, pp. 159-173 (1978) (15 pages).
Webster's Third New International Dictionary of the English Language (Unabridged), definitions of “deploy” and “deployment”, p. 605 (2002) (4 pages).
Histology of the Human Eye, An Atlas and Textbook, Chapter Eight: Choroid (1971) (74 pages).
Transcend Medical, Inc.'s Initial Disclosures, Served Jul. 30, 2013.
Glaukos Corporation's Initial Disclosures, Served Jul. 30, 2013.
Transcend Medical, Inc.'s Supplemental Disclosures, Served Nov. 14, 2014.
Glaukos Corporation's Supplemental Disclosures, Served Oct. 29, 2014.
Deposition of John Richards, Dated Jun. 17, 2015.
Deposition Jay Katz Dated Jun. 10, 2015.
Deposition Jay Katz, Dated Oct. 1, 2014.
Transcend Medical, Inc.'s Responses and Objections to Glaukos Corporation's First Set of Requests for Admission, Served Aug. 29, 2014.
Markman Hearing Transcript before Honorable Mitchell S. Goldberg, Dated Nov. 13, 2014.
Transcend Medical, Inc.'s Answer to Counterclaims, Served Jan. 13, 2014.
Joint Claim Construction Statement, Filed Jun. 20, 2014.
Answer and Counterclaim, Filed Jan. 3, 2014.
First Amended Complaint for Declaratory Judgment of Patent Non-Infringement and Invalidity, Filed Dec. 16, 2013.
Expert Report of Harold (Hal) J. Walbrink Regarding the Invalidity of Various Claims of the Patents in Suit and the Obviousness of Certain Claim Elements (Mar. 9, 2015) (63 pages).
Expert Report of Richard Lewis, M.D. (Mar. 9, 2015) (79 pages).
Rebuttal Expert Report of John Richards (Apr. 24, 2015) (16 pages).
Rebuttal Expert Report of L. Jay Katz MD. (Apr. 24, 2015) (130 pages).
Rebuttal Expert Report of Richard Lewis, M.D. (Apr. 24, 2015) (39 pages).
Rebuttal Expert Report of Ron Yamamoto (Apr. 24, 2015) (65 pages).
Expert Supplemental Report of Harold (Hal) J. Walbrink Regarding the Invalidity of Various Claims of The Patents-in-suit and the Obviousness of Certain Claim Elements (May 8, 2015) (17 pages).
Transcend Medical, Inc.'s Second Supplemental Invalidity Contentions, Aug. 26, 2014, 39 pages.
Declaration of Joseph F. Jennings in Support of Glaukos's Opening Claim Construction Brief, Jul. 18, 2014, 237 pages.
Declaration of Dr. L. Jay Katz in Support of Glaukos's Opening Claim Construction Brief, Jul. 17, 2014, 78 pages.
Glaukos' Opening Claim Construction Brief, Jul. 18, 2014, 30 pages.
Transcends's Answering Claim Construction Brief, Aug. 15, 2014, 461 pages.
Glaukos Corporation's Reply Claim Construction Brief, Aug. 29, 2014, 14 pages.
Transcend Medical, Inc.'s Redacted Second Amended Complaint for Declaratory Judgment of Patent Non-Infringement, Invalidity and Unenforceability, Sep. 10, 2014, 206 pages.
Transcend Medical, Inc.'s Redacted Exhibit A to the Stipulation and Proposed Order for Second Amended Complaint and Amendment of Scheduling Order, Sep. 11, 2014, 205 pages.
Transcend Medical, Inc's Redacted Sur-Reply Claim Construction Brief, Sep. 17, 2014, 14 pages.
Glaukos Corporation's Redacted Answer and Counterclaims to the Second Amended Complaint for Declaratory Judgment, Sep. 29, 2014, 27 pages.
Transcend's Answer to Counterclaims, Oct. 17, 2014, 10 pages.
G.B. Bietti, “The Present State of the Use of Plastics in Eye Surgery,” Acta Ophthalmologica, vol. 33, No. 4, 1955, pp. 337-370, 34 pages.
Cullen et al., “Anterior Chamber to Frontal Sinus Shunt for the Diversion of Aqueous Humor: A Pilot Study in Four Normal Dogs,” Veterinary Ophthalmology, vol. 1, No. 1, 1998, pp. 31-39, 9 pages.
M. A. Coote, “Glaucoma Hollow Fiber Filters—A New Glaucoma Seton. Preliminary Results,” J. Glaucoma, vol. 8, No. 1, Supplement, 1999, p. S4, 1 page.
L. Krejci, “Cyclodialysis with Hydroxyethyl Methacrylate Capillary Strip (HCS),” Opthalmologica, vol. 164, 1972, pp. 113-121, 9 pages.
P.F. Lee and C.L. Schepens, “Aqueous-venous Shunt and Intraocular Pressure. Preliminary Report of Animal Studies,” Investigative Opthalmology, vol. 5, No. 1, Feb. 1966, pp. 59-64, 6 pages.
S. Odrich, “New Technique During Complex Tube-Shunt Implantation,” Journal of Glaucoma, vol. 9, No. 3, 2000, pp. 278-289, 2 pages.
G.L. Portney, “Silicone Elastomer Implantation Cyclodialysis,” Archives of Ophthalmology, vol. 89, No. 1, Jan. 1973, pp. 10-12, 3 pages.
D. Spiegel, K. Kobuch, R. Hill, R. Gross, “Schlemm's Canal Implant: A New Method to Lower Intraocular Pressure in Patients with POAG?”, Opthalmic Surgery and Lasers, vol. 30, No. 6, Jun. 1999, pp. 492-494, 3 pages.
M.U. Troncoso, “Cyclodialysis with Insertion of a Metal Implant in the Treatment of Glaucoma,” Archives of Ophthalmology, vol. 23, 1940, pp. 270-300, 31 pages.
M.U. Troncoso, “Use of Tantalum Implants for Inducing a Permanent Hypotony in Rabbits' Eyes,” American Journal of Ophthalmology, vol. 32, No. 4, Apr. 1949, pp. 499-508, 10 pages.
Excerpts from the certified Deposition Transcript of Richard A. Hill, M.D., Jul. 17, 2014, pp. 1, 3-4, 240-253, and 270.
Excerpts from the certified Deposition Transcript of Gregory Smedley, Ph.D., Aug. 6, 2014, pp. 1, 3-4, 6-7, 12, 99-102, 106-114, and 203.
Deposition Transcript of M. Bruce Shields dated Jun. 3, 2015 [Redacted-Public Version].
Memorandum Opinion re Claim Construction dated Jan. 16, 2015.
Order re Claim Construction dated Jan. 16, 2015.
Glaukos's Motion for Summary Judgment on Transcend's Third Cause of Action for a Declaratory Judgment of Unenforceability for Inequitable Conduct dated Jun. 12, 2015.
Glaukos's Opening Brief in Support of Glaukos's Motion for Summary Judgment on Transcend's Third Cause of Action for a Declaratory Judgment of Unenforceability for Inequitable Conduct dated Jun. 12, 2015.
Glaukos's Statement of Undisputed Material Fact dated Jun. 12, 2015.
Transcend's Motion for Summary Judgment of Invalidity dated Jun. 12, 2015.
Transcend's Motion for Summary Judgment of Non-Infringement dated Jun. 12, 2015.
Transcend's Memorandum in Support of Transcend's Motion for Summary Judgment of Invalidity dated Jun. 19, 2015 [Redacted-Public Version].
Transcend's Statement of Undisputed Facts in Support of Transcend's Motion for Summary Judgment of Invalidity dated Jun. 19, 2015 [Redacted-Public Version].
Declaration of Vasquez in Support of Transcend's Motion for Summary Judgment of Non-Infringement dated Jun. 19, 2015 [Redacted-Public Version].
Declaration of Du Vergier in Support of Transcend's Motion for Summary Judgment of Non-Infringement dated Jun. 19, 2015 [Redacted-Public Version].
Response to Office Action Dated Sep. 18, 2009 (dated Mar. 18, 2010) from the prosecution history of U.S. Pat. No. 8,075,511 to Tu et al.
L. Jay Katz, Ciliochoroidal Detachment, 18:3 Ophthalmic Surgery 175, (Mar. 1987).
Tin A. Tun et al.,“Measurement of Trabecular Meshwork Width Using Swept Source Optical Coherence Tomography—Abstract” (May 2012) available at: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=6e904fa6-4f1b-406a-8fd9-3ad7551c527d&cKey=80031868-31bf-4b5e-8043-d3e5aedc7bf0 (last visited Jun. 12, 2015).
Tin A. Tun et al., Assessment of Trabecular Meshwork Width Using Swept Source Optical Coherence Tomography, 251:6 Graefes Arch. Clin. Exp. Ophthalmol. 1587 (2013).
“Transcend Medical CyPass® System—Instructions for Use,” (Release date Apr. 29, 2013).
Hady Saheb et al., Optical Coherence Tomography of the Suprachoroid After CyPass Micro-Stent Implantation for the Treatment of Open-Angle Glaucoma, Br. J. Ophthalmology, 98:19-23 (2014).
Helmut Hoeh et al., Early Postoperative Safety and Surgical Outcomes After Implantation of a Suprachoroidal Micro-Stent for the Treatment of Open-Angle Glaucoma Concomitant with Cataract Surgery, 39 J. Cataract Refract. Surg. 431 (2013).
Nir Shoham-Hazon et al., “Stability and Predictive Value of OCT Findings After CyPass Suprachoroidal Micro-Stent Implantation,” available at: http://transcendmedical.com/wp-content/uploads/2014/12/TM-AGS-2012-F2-final.pdf (last visited Jun. 12, 2015).
Schocket, Investigations of the Reasons for Success and Failure in the Anterior Shunt-to-the Encircling-Band Procedure in the Treatment of Refractory Glaucoma, Tr. Am. Ophth. Soc., 84:743 (1986).
Tsontcho Ianchulev, Chapter 21: The CyPass Suprachoroidal Micro-Stent, in J.R. Samples & I.I.K. Ahmed (eds.), Surgical Innovations in Glaucoma 229 (Springer Science+Business Media 2014).
Excerpt of Ramesh C. Tripathi & Brenda J. Tripathi, Chapter 1: Anatomy of the Human Eye, Orbit, and Adnexa, in Ramesh C. Tripathi & Brenda J. Tripathi, The Eye (Academic Press, Inc. 1984).
Final Office Action (dated Jun. 9, 2014) from the prosecution history of U.S. Appl. No. 13/786,357.
Tsontcho Ianchulev, Chapter 3: Suprachoroidal Space as a Therapeutic Target, in J.R. Samples & I.I.K. Ahmed (eds.), Surgical Innovations in Glaucoma 33 (Springer Science+Business Media 2014).
Declaration of Alyse Katz in Support of Motion for Summary Judgment of Invalidity dated Jun. 19, 2015 [Redacted-Public Version].
U.S. Appl. No. 60/281,973, entitled “Glaucoma Shunt and Methods Thereof for Glaucoma Treatment,” to Tu (filed Apr. 17, 2001).
Communication of the Board of Appeal Pursuant to Article 15(1) of the Rules of Procedure of the Boards of Appeal, submitted in the prosecution history of EP1977724, dated May 8, 2014 (Board of Appeal Communication, EP1977724.
Decision of Technical Board of Appeal 3.2.08 of Jan. 15, 2015, submitted in the prosecution history of EP1977724, dated Jan. 15, 2015.
Webpage regarding the definition of “subchoroidal” from Merriam Webster's Medical Dictionary, available at: http://www.merriam-webster.com/medical/subchoroidal (last visited Jun. 11, 2015).
Petition to Correct Inventorship in a Patent Pursuant to 35 U.S.C. § 256 and 37 C.F.R. § 1.324, filed in the prosecution history of U.S. Pat. No. 7,857,782 dated May 2014.
Petition to Correct Inventorship in a Patent Pursuant to 35 U.S.C. § 256 and 37 C.F.R. § 1.324, filed in the prosecution history of U.S. Pat. No. 8,075,511 dated May 2014.
Petition to Correct Inventorship in a Patent Pursuant to 35 U.S.C. § 256 and 37 C.F.R. § 1.324, filed in the prosecution history of U.S. Pat. No. 8,579,846 dated May 2014.
Correspondence from the U.S. Patent and Trademark Office granting the petition to correct inventorship, filed in the prosecution history of U.S. Pat. No. 7,857,782 (dated Nov. 18, 2014).
Correspondence from the U.S. Patent and Trademark Office granting the petition to correct inventorship, filed in the prosecution history of U.S. Pat. No. 8,075,511 (dated Oct. 31, 2014).
Correspondence from the U.S. Patent and Trademark Office granting the petition to correct inventorship, filed in the prosecution history of U.S. Pat. No. 8,579,846 (dated Feb. 10, 2015).
Declaration of Joshua Stowell in Support of Glaukos's Motion for Summary Judgment on Transcend's Third Cause of Action for a Declaratory Judgment of Unenforceability for Inequitable Conduct dated Jun. 19, 2015 [Redacted-Public Version].
Excerpts from the file history of U.S. Pat. No. 7,563,241 dated Mar. 13, 2009.
Transcend's Responses and Objections to Glaukos Corporation's Fifth Set of Interrogatories dated Nov. 20, 2014.
Transcend's First Supplemental Response to Glaukos Corporation's Interrogatory Nos. 17 and 18 dated May 13, 2014.
Excerpts from the certified Deposition Transcript of Barbara Niksch, dated Jun. 6, 2014.
Office Action from the USPTO dated Jun. 28, 2010 and Glaukos's response to that Office Action from the file history of U.S. Pat. No. 8,075,511.
Office Action from the USPTO dated Sep. 18, 2009 and Glaukos's response to that Office Action from the file history of U.S. Pat. No. 8,075,511.
Notice of Allowance issued by the USPTO from the file history of U.S. Pat. No. 8,579,846 (signed by Examiner Jul. 31, 2013).
Excerpts from the certified Deposition Transcript of David Haffner, dated May 28, 2014.
Declaration of Richard Lewis M.D. In Support of Glaukos's Oppositions to Transcend's Motions for Summary Judgment of Non-Infringement and Invalidity dated Jul. 2, 2015.
Declaration of Ron Yamamoto in Support of Glaukos's Opposition to Transcend's Motion for Summary Judgment of Invalidity dated Jul. 2, 2015.
Declaration of John Richards in Support of Glaukos's Opposition to Transcend's Motion for Summary Judgment of Invalidity dated Jul. 2, 2015.
Glaukos's Opposition to Transcend's Motion for Summary Judgment of Invalidity dated Jul. 2, 2015.
Transcend's Memorandum in Opposition to Glaukos' Motion for Summary Judgment of No Inequitable Conduct dated Jul. 9, 2015 [Redacted-Public Version].
Declaration of Julien Du Vergier in Support of Transcend's Opposition to Glaukos' Motion for Summary Judgment of No Inequitable Conduct dated Jul. 9, 2015 [Redacted-Public Version].
Transcend's Response and Statement of Further Undisputed Facts in Support of its Opposition to Glaukos' Motion for Summary Judgment of No Inequitable Conduct dated Jul. 9, 2015 [Redacted-Public Version].
Website entitled, “About Glaukos—History,” available at: http://www.glaukos.com/about-glaukos/history (last accessed Jun. 29, 2015).
Excerpt from the prosecution history of U.S. Pat. No. 7,857,782, including the Inventor Declaration dated Jun. 14, 2002.
Excerpt from the prosecution history of U.S. Pat. No. 8,075,511, including the Inventor Declaration dated Jun. 14, 2002.
Excerpt from the prosecution history of U.S. Pat. No. 8,579,846, including the Inventor Declaration dated Jun. 14, 2002.
Excerpt from the prosecution history of U.S. Appl. No. 09/549,350, including the Inventor Declaration (dated Aug./Sep. 2000).
Excerpt from the prosecution history of U.S. Appl. No. 09/704,276, including the Inventor Declaration (dated Feb. 2001).
U.S. Appl. No. 09/704,276, filed Nov. 1, 2000 [now U.S. Pat. No. 6,736,791].
Excerpt of the transcript from the deposition of David Schetter on Dec. 18, 2014.
U.S. Appl. No. 60/276,609, filed Mar. 16, 2001.
Request for Correction of Inventorship Under 37 C.F.R. § 1.48(d), dated May 27, 2014 and filed in the prosecution history of U.S. Appl. No. 60/281,973.
“Changing Perspectives in Glaucoma Management,” Innovations in Glaucoma 2010.
Richard Hill, MD, “Inventor's Perspective,” Glaucoma Today (Nov./Dec. 2012).
Website entitled, “2013 Ophthalmology Innovation Summit Innovator Awards,” dated Nov. 14, 2013 available at: http://ois.net/2013-ophthalmology-innovator-award/ (last visited Jun. 29, 2015).
Excerpt of Transcend's First Set of Interrogatories to Defendant Glaukos Corporation dated Jul. 16, 2013.
Excerpt of Transcend's First Set of Requests for Production to Defendant Glaukos Corporation dated Jul. 16, 2013.
Subpoena to Produce Documents, Information, or Objects or to Permit Inspection of Premises in a Civil Action propounded on Dr. Richard A. Hill, Feb. 11, 2014.
Glaukos's Opposition to Transcend's Motion for Summary Judgment of Non-Infringement dated Jul. 9, 2015 [Redacted-Public Version].
Glaukos's Statement of Material Facts that Present Genuine Issues for Trial in Opposition to Transcend's Motion for Summary Judgment of Non-Infringement dated Jul. 9, 2015 [Redacted-Public Version].
Declaration of L. Jay Katz in Support of Glaukos's Oppositions to Transcend's Motions for Summary Judgment of Non-Infringement and Invalidity dated Jul. 9, 2015 [Redacted-Public Version].
Declaration of Joshua Stowell in Support of Glaukos's Opposition to Transcend's Motion for Summary Judgment of Invalidity dated Jul. 9, 2015 [Redacted-Public Version].
Excerpts from the certified Deposition Transcript of Richard Lewis, M.D., dated Jun. 5, 2015.
Excerpts from the certified Deposition Transcript of Joseph Caprioli, M.D., dated May 27, 2015.
Excerpts from the certified Deposition Transcript of Ron Yamamoto, dated May 22, 2015.
Glaukos's Statement of Material Facts that Present Genuine Issues for Trial in Opposition to Transcend's Motion for Summary Judgment of Invalidity dated Jul. 9, 2015 [Redacted-Public Version].
Declaration of Joseph F. Jennings in Support of Glaukos's Opposition to Transcend's Motion for Summary Judgment of Non-Infringement dated Jul. 9, 2015 [Redacted-Public Version].
Duane's Ophthalmology on CD-ROM, 2006 Edition, Chapter 56—Medical Therapy of Glaucoma by Marc Weitzman and Joseph Caprioli.
Transcend's Reply in Support of its Motion for Summary Judgment of Invalidity dated Jul. 17, 2015 [Redacted-Public Version].
Declaration of Alyse L. Katz in Support of Transcend's Reply in Support of its Motion for Summary Judgment of Invalidity [Redacted-Public Version].
Amendment and Response to Office Action, filed in the prosecution of U.S. Appl. No. 13/786,357 on May 6, 2014.
Transcend's Reply in Support of its Motion for Summary Judgment of Non-Infringement dated Jul. 17, 2015 [Redacted-Public Version].
Declaration of Julien Du Vergier in Support of Transcend's Reply in Support of its Motion for Summary Judgment of Non-Infringement dated Jul. 17, 2015 [Redacted-Public Version].
Glaukos's Reply in Support of its Motion for Summary Judgment on Transcend's Third Cause of Action for a Declaratory Judgment of Unenforceability for Inequitable Conduct dated Jul. 17, 2015 [Redacted-Public Version].
Second Declaration of Joshua Stowell in Support of Glaukos's Motion for Summary Judgment on Transcend's Third Cause of Action for a Declaratory Judgment of Unenforceability for Inequitable Conduct dated Jul. 17, 2015 [Redacted-Public Version].
Transcend's Letter to Judge Regarding Citation Errors and Missing Exhibit Pages in Briefing Papers dated Jul. 28, 2015.
Memorandum Opinion in connection with Summary Judgment on the Issue of Invalidity, dated Sep. 18, 2015.
Order Granting in Part and Denying in Part Transcend Medical, Inc.'s Motion for Summary Judgment of Invalidity, dated Sep. 18, 2015.
Memorandum Opinion in connection with Summary Judgment on the Issue of Infringement, dated Sep. 18, 2015.
Order Granting Transcend Medical Inc.'s Motion for Summary Judgment of Non-Infringement, dated Sep. 18, 2015.
Memorandum Opinion in connection with Summary Judgment Regarding Unenforceability due to Inequitable Conduct, dated Sep. 18, 2015.
Order Denying Glaukos Corporation's Motion for Summary Judgment Regarding Unenforceability due to Inequitable Conduct, dated Sep. 18, 2015.
Proposed Pretrial Order, dated Sep. 30, 2015.
Declaration of Joseph F. Jennings in Support of Glaukos's Opening Claim Construction Brief (Jul. 18, 2014) (237 pages).
Transcend Medical, Inc.'s Responses and Objections to Glaukos Corporation's Fourth Set of Interrogatories, Served Aug. 29, 2014 [Redacted-Public Version].
Transcend's Memorandum in Support of Transcend's Motion for Summary Judgment of Non-Infringement dated Jun. 19, 2015 [Redacted-Public Version].
Transcend's Statement of Undisputed Facts in Support of Transcend's Motion for Summary Judgment of Non-Infringement dated Jun. 19, 2015 [Redacted-Public Version].
Jordan et al., Cyclodialysis ab interno as a surgical approach to intractable glaucoma, Graefe's Arch Clin Exp Opthalmol (2007) 245, pp. 1071-1076.
Tsontcho Ianchulev et al., “Minimally Invasive Ab-Interno Suprachoroidal Device (CyPass) for IOP Control in Open-Angle Glaucoma,” presented at the Annual Meeting of the American Academy of Ophthalmology Oct. 16-19, 2010, Chicago, IL.
Partial File History of U.S. Pat. No. 6,638,239 (Apr. 14, 2000) (36 pages).
Office Action in U.S. Appl. No. 12/111,033 (Sep. 18, 2009) (10 pages).
Response to Office Action in U.S. Appl. No. 12/111,033 (Mar. 18, 2010) (15 pages).
Interview Summary in U.S. Appl. No. 12/979,249, mailed May 29, 2013.
Notice of Allowance in U.S. Appl. No. 12/979,249, mailed Jun. 3, 2014.
Notice of Allowance in U.S. Appl. No. 12/979,249, mailed Oct. 1,2014.
Notice of Allowance in U.S. Appl. No. 12/979,249, mailed Jan. 21, 2015.
Notice of Allowance in U.S. Appl. No. 12/979,249, mailed Feb. 25, 2016.
Amendment and Response to Office Action in U.S. Appl. No. 13/786,357 (May 6, 2014) (46 pages).

Related Publications (1)

	Number	Date	Country
	20130245532 A1	Sep 2013	US

Provisional Applications (1)

	Number	Date	Country
	60281973	Apr 2001	US

Divisions (1)

	Number	Date	Country
Parent	11598542	Nov 2006	US
Child	12366508		US

Continuations (3)

	Number	Date	Country
Parent	13301648	Nov 2011	US
Child	13786363		US
Parent	12366508	Feb 2009	US
Child	13301648		US
Parent	10118578	Apr 2002	US
Child	11598542		US

Ocular disorder treatment methods and systems

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

US

CPC

International Classifications

Disclaimer

Abstract